CA2984178C - Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy - Google Patents
Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy Download PDFInfo
- Publication number
- CA2984178C CA2984178C CA2984178A CA2984178A CA2984178C CA 2984178 C CA2984178 C CA 2984178C CA 2984178 A CA2984178 A CA 2984178A CA 2984178 A CA2984178 A CA 2984178A CA 2984178 C CA2984178 C CA 2984178C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- allogeneic
- population
- ebv
- lpd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 title claims abstract description 213
- 238000000034 method Methods 0.000 title abstract description 63
- 238000002659 cell therapy Methods 0.000 title description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 415
- 230000000735 allogeneic effect Effects 0.000 claims abstract description 299
- 238000009096 combination chemotherapy Methods 0.000 claims abstract description 120
- 238000001959 radiotherapy Methods 0.000 claims abstract description 43
- 238000002560 therapeutic procedure Methods 0.000 claims description 93
- 108700028369 Alleles Proteins 0.000 claims description 80
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 78
- 229960004397 cyclophosphamide Drugs 0.000 claims description 78
- 238000011282 treatment Methods 0.000 claims description 59
- 210000004027 cell Anatomy 0.000 claims description 57
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 53
- 229960004618 prednisone Drugs 0.000 claims description 53
- 229960004641 rituximab Drugs 0.000 claims description 38
- 229940124292 CD20 monoclonal antibody Drugs 0.000 claims description 33
- 239000000427 antigen Substances 0.000 claims description 32
- 108091007433 antigens Proteins 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 210000000056 organ Anatomy 0.000 claims description 29
- 239000007787 solid Substances 0.000 claims description 26
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 25
- 229960004584 methylprednisolone Drugs 0.000 claims description 25
- 230000004044 response Effects 0.000 claims description 22
- 238000001802 infusion Methods 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 12
- 210000003734 kidney Anatomy 0.000 claims description 12
- 210000003169 central nervous system Anatomy 0.000 claims description 10
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 10
- 210000004185 liver Anatomy 0.000 claims description 10
- 206010025323 Lymphomas Diseases 0.000 claims description 9
- 210000004556 brain Anatomy 0.000 claims description 9
- 238000001990 intravenous administration Methods 0.000 claims description 9
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 7
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 7
- 210000000496 pancreas Anatomy 0.000 claims description 7
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 6
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 6
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 6
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 6
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 6
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 6
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 101150059079 EBNA1 gene Proteins 0.000 claims description 5
- 101150113929 EBNA2 gene Proteins 0.000 claims description 5
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims description 5
- 101150113776 LMP1 gene Proteins 0.000 claims description 5
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims description 5
- 210000004700 fetal blood Anatomy 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 claims description 5
- 210000005259 peripheral blood Anatomy 0.000 claims description 5
- 239000011886 peripheral blood Substances 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 210000000265 leukocyte Anatomy 0.000 claims description 3
- KQZSMOGWYFPKCH-UJPCIWJBSA-N (8s,9s,10r,11s,13s,14s,17r)-17-acetyl-11,17-dihydroxy-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)C[C@@H]2O KQZSMOGWYFPKCH-UJPCIWJBSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 52
- 230000001235 sensitizing effect Effects 0.000 description 36
- 238000000338 in vitro Methods 0.000 description 32
- 229960004528 vincristine Drugs 0.000 description 28
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 28
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 28
- 229960004679 doxorubicin Drugs 0.000 description 26
- 229960005420 etoposide Drugs 0.000 description 22
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 22
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 229960000684 cytarabine Drugs 0.000 description 17
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 229960000485 methotrexate Drugs 0.000 description 16
- 229960003957 dexamethasone Drugs 0.000 description 15
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 14
- 239000002246 antineoplastic agent Substances 0.000 description 13
- 229940127089 cytotoxic agent Drugs 0.000 description 13
- 210000001616 monocyte Anatomy 0.000 description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 210000004443 dendritic cell Anatomy 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108010006654 Bleomycin Proteins 0.000 description 9
- 229960001561 bleomycin Drugs 0.000 description 9
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229960000390 fludarabine Drugs 0.000 description 8
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 238000010257 thawing Methods 0.000 description 7
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 6
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 6
- 229960005277 gemcitabine Drugs 0.000 description 6
- 229910052697 platinum Inorganic materials 0.000 description 6
- 206010061598 Immunodeficiency Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000000973 chemotherapeutic effect Effects 0.000 description 5
- 229960003444 immunosuppressant agent Drugs 0.000 description 5
- 230000001861 immunosuppressant effect Effects 0.000 description 5
- 239000003018 immunosuppressive agent Substances 0.000 description 5
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 5
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 5
- 229960000624 procarbazine Drugs 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 229960003048 vinblastine Drugs 0.000 description 5
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 5
- 101000979735 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial Proteins 0.000 description 4
- 102100024975 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial Human genes 0.000 description 4
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 4
- 229960001467 bortezomib Drugs 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 4
- 229960001101 ifosfamide Drugs 0.000 description 4
- 230000002998 immunogenetic effect Effects 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 4
- 229960004964 temozolomide Drugs 0.000 description 4
- 229960002066 vinorelbine Drugs 0.000 description 4
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 3
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 3
- 108700034306 PROMACE-CytaBOM protocol Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229960001220 amsacrine Drugs 0.000 description 3
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940075234 cytogam Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 3
- 235000008191 folinic acid Nutrition 0.000 description 3
- 239000011672 folinic acid Substances 0.000 description 3
- 229960002963 ganciclovir Drugs 0.000 description 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 3
- 229960000908 idarubicin Drugs 0.000 description 3
- 229960001691 leucovorin Drugs 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
- 229960004961 mechlorethamine Drugs 0.000 description 3
- 229960001156 mitoxantrone Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 229960003433 thalidomide Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- IMBXRZKCLVBLBH-OGYJWPHRSA-N cvp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 IMBXRZKCLVBLBH-OGYJWPHRSA-N 0.000 description 2
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 2
- -1 etoposi de Chemical compound 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000009092 lines of therapy Methods 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000011521 systemic chemotherapy Methods 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 238000002726 Auger therapy Methods 0.000 description 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000002711 conventional external beam radiation therapy Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002721 intensity-modulated radiation therapy Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 1
- 238000002727 particle therapy Methods 0.000 description 1
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 description 1
- IXJYMUFPNFFKIB-FMONCPFKSA-N pomp protocol Chemical compound S=C1N=CNC2=C1NC=N2.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 IXJYMUFPNFFKIB-FMONCPFKSA-N 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- INIBXSLTWQVIHS-ASACRTLUSA-O stanford v protocol Chemical compound ClCCN(C)CCCl.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C INIBXSLTWQVIHS-ASACRTLUSA-O 0.000 description 1
- 238000009199 stereotactic radiation therapy Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000007483 tonsillectomy Methods 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960002149 valganciclovir Drugs 0.000 description 1
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 1
- 229950000815 veltuzumab Drugs 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 238000002728 volumetric modulated arc therapy Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed herein are methods of treating an EBV-LPD (Epstein-Barr Virus- associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD, comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells.
Description
METHODS OF TREATING EPSTEIN-BARR VIRUS-ASSOCIATED
LYMPHOPROLIFERATIVE DISORDERS BY T CELL THERAPY
1. FIELD
LYMPHOPROLIFERATIVE DISORDERS BY T CELL THERAPY
1. FIELD
[0002] Disclosed herein are methods of treating an EBV-LPD (Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD, comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T
cells.
2. BACKGROUND
cells.
2. BACKGROUND
[0003] Epstein-Barr Virus-associated lymphoproliferative disorders (EBV-LPDs) are a significant cause of morbidity and mortality for solid organ transplant recipients, hematopoietic stem cell transplant recipients, and other immunocompromised patients. Different therapies have been developed to treat EBV-LPDs, such as chemotherapy, combination chemotherapy, radiation therapy, therapy with rituximab (an anti-CD20 monoclonal antibody), and cellular immunotherapy (see, for example, Elstrom et al., 2006, Am J Transplant 6:569-576; Hague et al, 2001, Transplantation 72:1399-1402; Hague et al, 2002, Lancet 360:435-442; Gandhi et al, 2007, American Journal of Transplantation 7:1293-1299; and Doubrovina, E., et al., Blood, 2012. 119:
2644-2656). In situations where a first-line therapy has failed, later lines of therapy are often attempted. For example, for many SOT recipients, especially those with low grade disease, the first-line of treatment is decreasing dosage of immunosuppressant given to the patient. Several authors have reported efficacy of single agent rituximab in patients who failed to respond to reduction in immunosuppressant dosage (see, for example, Webber et al, 2004, Blood 104:
Abstract 746; and Messahel et al, 2006, Leuk Lymphoma 47:2584-2589). If patients relapse Date Recue/Date Received 2021-05-11 after responding to rituximab or fail to respond to rituximab, there is no consensus in terms of whether re-treating with single agent rituximab is worthwhile and many centers will proceed to combination chemotherapy. The Children's Oncology Group recently completed a trial of low dose cyclophosphamide, steroids and rituximab with 2 year EFS (event free survival) of 71% and OS (overall survival) of 83% (Gross et al., 2012, Am J Transplant 12:3069-3075). In adult patients the treatment is more varied and includes R-CHOP (a therapy regimen with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab) or DA-EPOCH (Dose-Adjusted EPOCH, which is a therapy regimen with etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin). In patients with CNS (central nervous system) involvement of EBV-LPD, regimens include intrathecal rituximab, radiation or high dose methotrexate alone for CNS only disease, or in combination for systemic and CNS disease.
2644-2656). In situations where a first-line therapy has failed, later lines of therapy are often attempted. For example, for many SOT recipients, especially those with low grade disease, the first-line of treatment is decreasing dosage of immunosuppressant given to the patient. Several authors have reported efficacy of single agent rituximab in patients who failed to respond to reduction in immunosuppressant dosage (see, for example, Webber et al, 2004, Blood 104:
Abstract 746; and Messahel et al, 2006, Leuk Lymphoma 47:2584-2589). If patients relapse Date Recue/Date Received 2021-05-11 after responding to rituximab or fail to respond to rituximab, there is no consensus in terms of whether re-treating with single agent rituximab is worthwhile and many centers will proceed to combination chemotherapy. The Children's Oncology Group recently completed a trial of low dose cyclophosphamide, steroids and rituximab with 2 year EFS (event free survival) of 71% and OS (overall survival) of 83% (Gross et al., 2012, Am J Transplant 12:3069-3075). In adult patients the treatment is more varied and includes R-CHOP (a therapy regimen with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab) or DA-EPOCH (Dose-Adjusted EPOCH, which is a therapy regimen with etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin). In patients with CNS (central nervous system) involvement of EBV-LPD, regimens include intrathecal rituximab, radiation or high dose methotrexate alone for CNS only disease, or in combination for systemic and CNS disease.
[0004] EBV-LPDs resistant to a previous therapy that has shown to be effective clinically (for example, combination chemotherapy, radiation therapy, or therapy with rituximab) are harder to treat. The greater the degree of efficacy the previous therapy has shown to demonstrate clinically, and the more therapies the patient has failed, the greater the expectation of difficulty in achieving successful treatment by a later-line therapy. An EBV-LPD that is resistant to a previous therapy is usually more aggressive This is especially true when the previous therapy is chemotherapy or radiation therapy, which often leads to or selects for mutated tumor cells, resulting in a much more aggressive disease. First-line therapies are usually selected based on their desirable combination of safety and efficacy, while later lines of therapy are usually considered less desirable in terms of their safety and/or efficacy profiles.
Thus, there is a need for methods of treating EBV-LPD in patients who have failed combination chemotherapy and/or radiation therapy that have desirable safety and efficacy profiles.
Thus, there is a need for methods of treating EBV-LPD in patients who have failed combination chemotherapy and/or radiation therapy that have desirable safety and efficacy profiles.
[0005] Citation of a reference herein shall not be construed as an admission that such is prior art to the present disclosure.
3. SUMMARY OF THE INVENTION
3. SUMMARY OF THE INVENTION
[0006] The present invention relates to methods of treating an EBV-LPD
(Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD.
(Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD.
[0007] In one aspect, provided herein are methods of treating an EBV-LPD in a human patient comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells; wherein the human patient has failed a combination chemotherapy to treat the EBV-LPD, and wherein the population of allogeneic T
cells is restricted by an human leukocyte antigen (HLA) allele shared with cells of the EBV-LPD. (The population of allogeneic T cells is human.) In certain embodiments, the EBV-LPD is resistant to the combination chemotherapy to treat the EBV-LPD. In certain embodiments, the human patient has been taken off the combination chemotherapy due to intolerance of the combination chemotherapy. In a specific embodiment, the combination chemotherapy that the human patient has failed comprises therapy with cyclophosphamide and prednisone. In a further specific embodiment, the combination chemotherapy that the human patient has failed comprises a low-dose cyclophosphamide and prednisone regimen. In another specific embodiment, the combination chemotherapy that the human patient has failed comprises therapy with cyclophosphamide and methylprednisolone. In another further specific embodiment, the combination chemotherapy that the human patient has failed comprises a low-dose cyclophosphamide and methylprednisolone regimen.
cells is restricted by an human leukocyte antigen (HLA) allele shared with cells of the EBV-LPD. (The population of allogeneic T cells is human.) In certain embodiments, the EBV-LPD is resistant to the combination chemotherapy to treat the EBV-LPD. In certain embodiments, the human patient has been taken off the combination chemotherapy due to intolerance of the combination chemotherapy. In a specific embodiment, the combination chemotherapy that the human patient has failed comprises therapy with cyclophosphamide and prednisone. In a further specific embodiment, the combination chemotherapy that the human patient has failed comprises a low-dose cyclophosphamide and prednisone regimen. In another specific embodiment, the combination chemotherapy that the human patient has failed comprises therapy with cyclophosphamide and methylprednisolone. In another further specific embodiment, the combination chemotherapy that the human patient has failed comprises a low-dose cyclophosphamide and methylprednisolone regimen.
[0008] In specific embodiments, the human patient also has failed multiple different combination chemotherapies to treat the EBV-LPD. In a particular embodiment, the EBV-LPD
is resistant to the multiple different combination chemotherapies to treat the EBV-LPD. In another particular embodiment, the human patient has been taken off the multiple different combination chemotherapies due to intolerance of the multiple different combination chemotherapies. In a specific embodiment, at least one of the multiple different combination chemotherapies that the human patient has failed comprises therapy with cyclophosphamide and prednisone. In a further specific embodiment, at least one of the multiple different combination chemotherapies that the human patient has failed comprises a low-dose cyclophosphamide and prednisone regimen In another specific embodiment, at least one of the multiple different combination chemotherapies that the human patient has failed comprises therapy with cyclophosphamide and methylprednisolone. In another further specific embodiment, at least one of the multiple different combination chemotherapies that the human patient has failed comprises a low-dose cyclophosphamide and methylprednisolone regimen.
is resistant to the multiple different combination chemotherapies to treat the EBV-LPD. In another particular embodiment, the human patient has been taken off the multiple different combination chemotherapies due to intolerance of the multiple different combination chemotherapies. In a specific embodiment, at least one of the multiple different combination chemotherapies that the human patient has failed comprises therapy with cyclophosphamide and prednisone. In a further specific embodiment, at least one of the multiple different combination chemotherapies that the human patient has failed comprises a low-dose cyclophosphamide and prednisone regimen In another specific embodiment, at least one of the multiple different combination chemotherapies that the human patient has failed comprises therapy with cyclophosphamide and methylprednisolone. In another further specific embodiment, at least one of the multiple different combination chemotherapies that the human patient has failed comprises a low-dose cyclophosphamide and methylprednisolone regimen.
[0009] In specific embodiments, the human patient who has failed a combination chemotherapy to treat the EBV-LPD (or multiple different combination chemotherapies) also has failed a radiation therapy to treat the EBV-LPD. In a particular embodiment, the EBV-LPD is resistant to the radiation therapy to treat the EBV-LPD. In another particular embodiment, the human patient has been taken off the radiation therapy due to intolerance of the radiation therapy.
[0010] In another aspect, provided herein are methods of treating an EBV-LPD in a human patient comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells; wherein the human patient has failed a radiation therapy to treat the EBV-LPD, and wherein the population of allogeneic T cells is restricted by an HLA
allele shared with cells of the EBV-LPD. In certain embodiments, the EBV-LPD
is resistant to the radiation therapy to treat the EBV-LPD. In certain embodiments, the human patient has been taken off the radiation therapy due to intolerance of the radiation therapy.
allele shared with cells of the EBV-LPD. In certain embodiments, the EBV-LPD
is resistant to the radiation therapy to treat the EBV-LPD. In certain embodiments, the human patient has been taken off the radiation therapy due to intolerance of the radiation therapy.
[0011] In various embodiments, wherein the EBV-LPD is a disorder of cells of B cell lineage, in addition to failing a combination chemotherapy (or multiple different combination chemotherapies) and/or a radiation therapy as described above, the human patient also has failed a therapy with an anti-CD20 monoclonal antibody to treat the EBV-LPD. In certain embodiments, the EBV-LPD is resistant to the therapy with the anti-CD20 monoclonal antibody to treat the EBV-LPD. In certain embodiments, the human patient has been taken off the therapy with the anti-CD20 monoclonal antibody due to intolerance of the therapy with the anti-CD20 monoclonal antibody. In a specific embodiment, the anti-CD20 monoclonal antibody is rituximab.
[0012] In specific embodiments, in addition to being restricted by an HLA
allele shared with the EBV-LPD, the population of allogeneic T cells comprising EBV-specific T cells shares at least 2 out of 8 HLA alleles with cells of the EBV-LPD. In a specific embodiment, the 8 HLA
alleles are two TILA-A alleles, two HLA-B alleles, two TrILA-C alleles, and two HLA-DR alleles.
allele shared with the EBV-LPD, the population of allogeneic T cells comprising EBV-specific T cells shares at least 2 out of 8 HLA alleles with cells of the EBV-LPD. In a specific embodiment, the 8 HLA
alleles are two TILA-A alleles, two HLA-B alleles, two TrILA-C alleles, and two HLA-DR alleles.
[0013] In specific embodiments, the methods of treating an EBV-LPD as described herein further comprise prior to the administering step a step of ascertaining at least one HLA
allele of cells of the EBV-LPD by high-resolution typing.
allele of cells of the EBV-LPD by high-resolution typing.
[0014] In various embodiments, the methods of treating an EBV-LPD further comprise prior to the administering step a step of generating the population of allogeneic T cells in vitro.
[0015] In specific embodiments, the step of generating the population of allogeneic T
cells in vitro comprises sensitizing allogeneic T cells to one or more EBV
antigens.
cells in vitro comprises sensitizing allogeneic T cells to one or more EBV
antigens.
[0016] In certain embodiments, the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using EBV-transformed B
cells. In a specific embodiment, the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using EBV strain B95.8-transformed B cells.
cells. In a specific embodiment, the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using EBV strain B95.8-transformed B cells.
[0017] In certain embodiments, the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using dendritic cells, cytokine-activated monocytes, or peripheral blood mononuclear cells. In specific embodiments, the step of sensitizing allogeneic T cells using dendritic cells, cytokine-activated monocytes, or peripheral blood mononuclear cells comprises loading the dendritic cells, the cytokine-activated monocytes, or the peripheral blood mononuclear cells with at least one immunogenic peptide derived from one or more EBV antigens In specific embodiments, the step of sensitizing allogeneic T cells using dendritic cells, cytokine-activated monocytes, or peripheral blood mononuclear cells comprises loading the dendritic cells, the cytokine-activated monocytes, or the peripheral blood mononuclear cells with a pool of overlapping peptides derived from one or more EBV antigens.
[0018] In certain embodiments, the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using artificial antigen-presenting cells (AAPCs). In specific embodiments, the step of sensitizing allogeneic T cells using AAPCs comprises loading the AAPCs with at least one immunogenic peptide derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T
cells using AAPCs comprises loading the AAPCs with a pool of overlapping peptides derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T
cells using AAPCs comprises engineering the AAPCs to express at least one immunogenic EBV
peptide or protein in the AAPCs.
cells using AAPCs comprises loading the AAPCs with a pool of overlapping peptides derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T
cells using AAPCs comprises engineering the AAPCs to express at least one immunogenic EBV
peptide or protein in the AAPCs.
[0019] In specific embodiments, the step of generating the population of allogeneic T
cells in vitro further comprises, after sensitizing, cryopreserving the allogeneic T cells.
cells in vitro further comprises, after sensitizing, cryopreserving the allogeneic T cells.
[0020] In specific embodiments, the methods of treating an EBV-LPD as described herein further comprise, before the administering step, steps of thawing cryopreserved EBV-antigen sensitized allogeneic T cells, and expanding the allogeneic T cells in vitro, to produce the population of allogeneic T cells.
[0021] In certain embodiments, the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of thawing a cryopreserved form of the population of allogeneic T cells.
[0022] In various embodiments, the population of allogeneic T cells is derived from a T
cell line. In certain embodiments, the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of selecting the T
cell line from a bank of a plurality of cryopreserved T cell lines. In certain embodiments, the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of thawing a cryopreserved form of the T cell line. In specific embodiments, the methods of treating an EBV-LPD as described herein further comprises, before the administering step, a step of expanding the T cell line in vitro.
cell line. In certain embodiments, the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of selecting the T
cell line from a bank of a plurality of cryopreserved T cell lines. In certain embodiments, the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of thawing a cryopreserved form of the T cell line. In specific embodiments, the methods of treating an EBV-LPD as described herein further comprises, before the administering step, a step of expanding the T cell line in vitro.
[0023] In specific embodiments, the EBV-specific T cells administered in accordance with the methods described herein recognizes an EBV antigen that is EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1 or LMP2.
[0024] In certain embodiments, the administering is by infusion of the population of allogeneic T cells. In some embodiments, the infusion is bolus intravenous infusion. In certain embodiments, the administering comprises administering at least about 1 x 10 T
cells of the population of allogeneic T cells per kg per dose per week to the human patient. In some embodiments, the administering comprises administering about 1 x 106 to about 2 x 106T cells of the population of allogeneic T cells per kg per dose per week to the human patient. In a specific embodiment, the administering comprises administering about 1 x 106 T cells of the population of allogeneic T cells per kg per dose per week to the human patient. In another specific embodiment, the administering comprises administering about 2 x 106T cells of the population of allogeneic T cells per kg per dose per week to the human patient.
cells of the population of allogeneic T cells per kg per dose per week to the human patient. In some embodiments, the administering comprises administering about 1 x 106 to about 2 x 106T cells of the population of allogeneic T cells per kg per dose per week to the human patient. In a specific embodiment, the administering comprises administering about 1 x 106 T cells of the population of allogeneic T cells per kg per dose per week to the human patient. In another specific embodiment, the administering comprises administering about 2 x 106T cells of the population of allogeneic T cells per kg per dose per week to the human patient.
[0025] In certain embodiments, the methods of treating an EBV-LPD as described herein comprise administering at least 2 doses of the population of allogeneic T
cells to the human patient. In specific embodiments, the methods of treating an EBV-LPD as described herein comprise administering 2, 3, 4, 5, or 6 doses of the population of allogeneic T cells to the human patient.
cells to the human patient. In specific embodiments, the methods of treating an EBV-LPD as described herein comprise administering 2, 3, 4, 5, or 6 doses of the population of allogeneic T cells to the human patient.
[0026] In certain embodiments, the methods of treating an EBV-LPD as described herein comprise administering a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period during which no dose of the population of allogeneic T cells is administered, followed by a second cycle of the one dose per week of the population of allogeneic T cells for 3 consecutive weeks. In specific embodiments, the methods of treating an EBV-LPD as described herein comprise administering two, three, four, five, or six cycles of one dose per week of the population of allogeneic T cells for 3 consecutive weeks, each cycle separated by a washout period during which no dose of the population of allogeneic T cells is administered. In a specific embodiment, the washout period is about three weeks.
[0027] In certain embodiments, the methods of treating an EBV-LPD further comprise, after administering to the human patient the population of allogeneic T cells, administering to the human patient a second population of allogeneic T cells comprising EBV-specific T cells;
wherein the second population of allogeneic T cells is restricted by a different HLA allele shared with cells of the EBV-LPD. In a specific embodiment, the methods of treating an EBV-LPD
comprise administering a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period during which no dose of the population of allogeneic T cells is administered, followed by a second cycle of one dose per week of the second population of allogeneic T cells for 3 consecutive weeks. In a further specific embodiment, the washout period is about three weeks.
wherein the second population of allogeneic T cells is restricted by a different HLA allele shared with cells of the EBV-LPD. In a specific embodiment, the methods of treating an EBV-LPD
comprise administering a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period during which no dose of the population of allogeneic T cells is administered, followed by a second cycle of one dose per week of the second population of allogeneic T cells for 3 consecutive weeks. In a further specific embodiment, the washout period is about three weeks.
[0028] In certain embodiments, the human patient has no response, an incomplete response, or a suboptimal response after administering the population of allogeneic T cells and prior to administering the second population of allogeneic T cells.
[0029] The human patient can be anyone who has an EBV-LPD and who has failed combination chemotherapy to treat the EBV-LPD (and in some embodiments, also has failed therapy with an anti-CD20 monoclonal antibody) and/or radiation therapy (and in some embodiments, also has failed therapy with an anti-CD20 monoclonal antibody).
[0030] In a specific embodiment, the EBV-LPD is an EBV-positive lymphoma.
In specific embodiments, the EBV-LPD treated in accordance with a method described herein is present in the central nervous system of the human patient In a specific embodiment, the EBV-LPD treated in accordance with a method described herein is present in the brain of the human patient.
In specific embodiments, the EBV-LPD treated in accordance with a method described herein is present in the central nervous system of the human patient In a specific embodiment, the EBV-LPD treated in accordance with a method described herein is present in the brain of the human patient.
[0031] In some embodiments, the human patient has been the recipient of a solid organ transplant from a transplant donor. In some embodiments, the human patient has been the recipient of multiple organ transplants (for example, heart and lung transplants, or kidney and pancreas transplants). The solid organ transplant can be, but is not limited to, a kidney transplant, a liver transplant, a heart transplant, an intestinal transplant, a pancreas transplant, a lung transplant, or a combination thereof. In a specific embodiment, the solid organ transplant is a kidney transplant. In another specific embodiment, the solid organ transplant is a liver transplant. In some embodiments, the human patient has been the recipient of a hematopoietic stem cell transplant (HSCT) from a transplant donor. The HSCT can be a bone marrow transplant, a peripheral blood stem cell transplant, or a cord blood transplant. In specific embodiments, the population of allogeneic T cells is derived from a donor other than the transplant donor.
4. DETAILED DESCRIPTION
4. DETAILED DESCRIPTION
[0032] The present invention relates to methods of treating an EBV-LPD
(Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD. This invention provides a T cell therapy method that is effective in treating EBV-LPD that is resistant to combination chemotherapy or to radiation therapy, and thus finds use as a later-line therapy with low toxicity.
(Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD. This invention provides a T cell therapy method that is effective in treating EBV-LPD that is resistant to combination chemotherapy or to radiation therapy, and thus finds use as a later-line therapy with low toxicity.
[0033] In one aspect, provided herein are methods of treating an EBV-LPD in a human patient comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells; wherein the human patient has failed a combination chemotherapy to treat the EBV-LPD, and wherein the population of allogeneic T
cells is restricted by an human leukocyte antigen (HLA) allele shared with cells of the EBV-LPD. In certain embodiments, the EBV-LPD is resistant to the combination chemotherapy to treat the EBV-LPD. In certain embodiments, the human patient has been taken off the combination chemotherapy due to intolerance of the combination chemotherapy. In specific embodiments, the human patient also has failed multiple different combination chemotherapies to treat the EBV-LPD. In a particular embodiment, the EBV-LPD is resistant to the multiple different combination chemotherapies to treat the EBV-LPD. In another particular embodiment, the human patient has been taken off the multiple different combination chemotherapies due to intolerance of the multiple different combination chemotherapies. In specific embodiments, the human patient also has failed a radiation therapy to treat the EBV-LPD. In a particular embodiment, the EBV-LPD is resistant to the radiation therapy to treat the EBV-LPD. In another particular embodiment, the human patient has been taken off the radiation therapy due to intolerance of the radiation therapy.
cells is restricted by an human leukocyte antigen (HLA) allele shared with cells of the EBV-LPD. In certain embodiments, the EBV-LPD is resistant to the combination chemotherapy to treat the EBV-LPD. In certain embodiments, the human patient has been taken off the combination chemotherapy due to intolerance of the combination chemotherapy. In specific embodiments, the human patient also has failed multiple different combination chemotherapies to treat the EBV-LPD. In a particular embodiment, the EBV-LPD is resistant to the multiple different combination chemotherapies to treat the EBV-LPD. In another particular embodiment, the human patient has been taken off the multiple different combination chemotherapies due to intolerance of the multiple different combination chemotherapies. In specific embodiments, the human patient also has failed a radiation therapy to treat the EBV-LPD. In a particular embodiment, the EBV-LPD is resistant to the radiation therapy to treat the EBV-LPD. In another particular embodiment, the human patient has been taken off the radiation therapy due to intolerance of the radiation therapy.
[0034] In another aspect, provided herein are methods of treating an EBV-LPD in a human patient comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells; wherein the human patient has failed a radiation therapy to treat the EBV-LPD, and wherein the population of allogeneic T cells is restricted by an HLA
allele shared with cells of the EBV-LPD. In certain embodiments, the EBV-LPD
is resistant to the radiation therapy to treat the EBV-LPD. In certain embodiments, the human patient has been taken off the radiation therapy due to intolerance of the radiation therapy.
allele shared with cells of the EBV-LPD. In certain embodiments, the EBV-LPD
is resistant to the radiation therapy to treat the EBV-LPD. In certain embodiments, the human patient has been taken off the radiation therapy due to intolerance of the radiation therapy.
[0035] In various embodiments, wherein the EBV-LPD is a disorder of cells of B cell lineage, in addition to failing a combination chemotherapy (or multiple different combination chemotherapies) and/or a radiation therapy as described above, the human patient also has failed a therapy with an anti-CD20 monoclonal antibody (for example, rituximab) to treat the EBV-LPD. In certain embodiments, the EBV-LPD is resistant to the therapy with the anti-CD20 monoclonal antibody to treat the EBV-LPD. In certain embodiments, the human patient has been taken off the therapy with the anti-CD20 monoclonal antibody due to intolerance of the therapy with the anti-CD20 monoclonal antibody.
[0036] A human patient is considered to have failed a therapy (e.g., combination chemotherapy, radiation therapy, and/or therapy with anti-CD20 monoclonal antibody) of EBV-LPD if the EBV-LPD is resistant to the therapy and/or if the human patient has been taken off the therapy due to intolerance of the therapy (for example, due to toxicity of the therapy in view of the patient's age or condition). An EBV-LPD is considered resistant to a therapy (e.g., combination chemotherapy, radiation therapy, or therapy with anti-CD20 monoclonal antibody), if the EBV-LPD has no response, or has an incomplete response (a response that is less than a complete remission), or progresses, or relapses after the therapy. A complete remission is a complete resolution of all clinical and radiologic evidence of the disease, optionally confirmed by biopsy of affected tissues, lasting for at least three weeks following completion of the therapy.
4.1. Combination Chemotherapies, Radiation Therapies, and Anti-CD20 Antibodies
4.1. Combination Chemotherapies, Radiation Therapies, and Anti-CD20 Antibodies
[0037] Combination chemotherapy involves the therapeutic use over the same treatment period of two or more different chemotherapeutic agents to treat cancer. A
chemotherapeutic agent is an anti-cancer cytotoxic chemical drug, generally a small molecule, synthetic organic compound, and is distinct from other types of anti-cancer agents such as biopolymers and cells.
Thus, chemotherapeutic agents are not nucleic acids, proteins (for example, antibodies), or immune cells (for example, T cells). Combination chemotherapy is often attempted in order to minimize potential resistance of the cancer (e.g., EBV-LPD) to the therapy.
This is because cancer cells could mutate to become resistant to a single chemotherapeutic agent, but by using different chemotherapeutic agents it would be more difficult for the cancer to mutate so as to develop resistance to the combination. Therefore, a combination chemotherapy-resistant EBV-LPD is usually considered harder to treat than a single agent-resistant EBV-LPD.
chemotherapeutic agent is an anti-cancer cytotoxic chemical drug, generally a small molecule, synthetic organic compound, and is distinct from other types of anti-cancer agents such as biopolymers and cells.
Thus, chemotherapeutic agents are not nucleic acids, proteins (for example, antibodies), or immune cells (for example, T cells). Combination chemotherapy is often attempted in order to minimize potential resistance of the cancer (e.g., EBV-LPD) to the therapy.
This is because cancer cells could mutate to become resistant to a single chemotherapeutic agent, but by using different chemotherapeutic agents it would be more difficult for the cancer to mutate so as to develop resistance to the combination. Therefore, a combination chemotherapy-resistant EBV-LPD is usually considered harder to treat than a single agent-resistant EBV-LPD.
[0038] The present invention provides for treatment of a human patient with EBV-LPD
who has failed a combination chemotherapy to treat the EBV-LPD. The combination chemotherapy that the human patient has failed can be any known in the art for treatment of a LPD (lymphoproliferative disorder). Exemplary combination chemotherapies include, but are not limited to (the combinations being of the chemotherapeutic agents in parentheses): 7+3 (7 days of cytarabine plus 3 days of an anthracycline antibiotic, either daunorubicin or idarubicin), ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), BACOD (bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone), BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone), Dose-Escalated BEACOPP, CBV
(cyclophosphamide, carmustine, etoposide), COP (cyclophosphamide, vincristine, and prednisone or prednisolone), CHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone), CEOP (cyclophosphamide, etoposide, vincristine, prednisone), CEPP
(cyclophosphamide, etoposide, procarbazine, prednisone), Ch1VPP (chlorambucil, vincristine, procarbazine, prednisone, etoposide, vinblastine, doxorubicin), CHOP
(cyclophosphamide, doxorubicin, vincristine, predni sone), DCEP (dexamethasone, cyclophosphamide, etoposi de, platinum agent), DHAP (dexamethasone, cytarabine, platinum agent), DICE
(dexamethasone, ifosfamide, cisplatin, etoposide), DT-PACE (dexamethasone, thalidomide, platinum agent, doxorubicin, cyclophosphamide, etoposide), EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), DA-EPOCH (Dose-Adjusted EPOCH), ESHAP
(etoposide, methylprednisolone, cytarabine, cisplatin), FCM (fludarabine, cyclophosphamide, mitoxantrone), FM (fludarabine, mitoxantrone), FLAG (fludarabine, cytarabine, G-CSF), FLAG-IDA
(fludarabine, cytarabine, idarubicin, G-CSF), FLAG-MITO (mitoxantrone, fludarabine, cytarabine, G-CSF), FLAMSA (fludarabine, cytarabine, amsacrine), FLAMSA-BU
(fludarabine, cytarabine, amsacrine, busulfan), FLAMSA-MEL (fludarabine, cytarabine, amsacrine, melphalan), GVD (gemcitabine, vinorelbine, pegylated liposomal doxorubicin), GEMOX
(gemcitabine, oxaliplatin), IAC (idarubicin x 3 days plus cytarabine x 7 days), ICE (ifosfamide, carboplatin, etoposide), IVAC (etopside, cytarabine, ifosfamide), m-BACOD
(methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone), MACOP-B
(methotrexate, leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin), MINE (mesna, ifosfamide, novantrone, etoposide), MOPP (mechlorethamine, vincristine, procarbazine, prednisone), MVP (mitomycin, vindesine, cisplatin), PACE
(platinum agent, doxorubicin, cyclophosphamide, etoposide), PEB (cisplatin, etoposide, bleomycin), POMP (6-mercaptopurine, vincristine, methotrexate, prednisone), ProMACE-MOPP
(methotrexate, doxorubicin, cyclophosphamide, etoposide, mechlorethamine, vincristine, procarbazine, prednisone), ProMACE-CytaBOM (prednisone, doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine, methotrexate, leucovorin), RVD
(lenalidomide, bortezomib, dexamethasone), Stanford V(doxorubicin, mechlorethamine, bleomycin, vinblastine, vincristine, etoposide, prednisone), Thal/Dex (thalidomide, dexamethasone), VAD
(vincristine, doxorubicin, dexamethasone), VAMP (vincristine, amethopterin, 6-mercaptopurine and prednisone, or vincristine, doxorubicin, methotrexate and prednisone, or vincristine, doxorubicin and methylprednisolone), VAPEC-B (vincristine, doxorubicin, prednisone, etoposide, cyclophosphamide, bleomycin), VD-PACE (bortezomib, dexamethasone, platinum agent, doxorubicin, cyclophosphamide, etoposide), and VTD-PACE (bortezomib, thalidomide, dexamethasone, platinum agent, doxorubicin, cyclophosphamide, etoposide).
who has failed a combination chemotherapy to treat the EBV-LPD. The combination chemotherapy that the human patient has failed can be any known in the art for treatment of a LPD (lymphoproliferative disorder). Exemplary combination chemotherapies include, but are not limited to (the combinations being of the chemotherapeutic agents in parentheses): 7+3 (7 days of cytarabine plus 3 days of an anthracycline antibiotic, either daunorubicin or idarubicin), ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), BACOD (bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone), BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone), Dose-Escalated BEACOPP, CBV
(cyclophosphamide, carmustine, etoposide), COP (cyclophosphamide, vincristine, and prednisone or prednisolone), CHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone), CEOP (cyclophosphamide, etoposide, vincristine, prednisone), CEPP
(cyclophosphamide, etoposide, procarbazine, prednisone), Ch1VPP (chlorambucil, vincristine, procarbazine, prednisone, etoposide, vinblastine, doxorubicin), CHOP
(cyclophosphamide, doxorubicin, vincristine, predni sone), DCEP (dexamethasone, cyclophosphamide, etoposi de, platinum agent), DHAP (dexamethasone, cytarabine, platinum agent), DICE
(dexamethasone, ifosfamide, cisplatin, etoposide), DT-PACE (dexamethasone, thalidomide, platinum agent, doxorubicin, cyclophosphamide, etoposide), EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), DA-EPOCH (Dose-Adjusted EPOCH), ESHAP
(etoposide, methylprednisolone, cytarabine, cisplatin), FCM (fludarabine, cyclophosphamide, mitoxantrone), FM (fludarabine, mitoxantrone), FLAG (fludarabine, cytarabine, G-CSF), FLAG-IDA
(fludarabine, cytarabine, idarubicin, G-CSF), FLAG-MITO (mitoxantrone, fludarabine, cytarabine, G-CSF), FLAMSA (fludarabine, cytarabine, amsacrine), FLAMSA-BU
(fludarabine, cytarabine, amsacrine, busulfan), FLAMSA-MEL (fludarabine, cytarabine, amsacrine, melphalan), GVD (gemcitabine, vinorelbine, pegylated liposomal doxorubicin), GEMOX
(gemcitabine, oxaliplatin), IAC (idarubicin x 3 days plus cytarabine x 7 days), ICE (ifosfamide, carboplatin, etoposide), IVAC (etopside, cytarabine, ifosfamide), m-BACOD
(methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone), MACOP-B
(methotrexate, leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin), MINE (mesna, ifosfamide, novantrone, etoposide), MOPP (mechlorethamine, vincristine, procarbazine, prednisone), MVP (mitomycin, vindesine, cisplatin), PACE
(platinum agent, doxorubicin, cyclophosphamide, etoposide), PEB (cisplatin, etoposide, bleomycin), POMP (6-mercaptopurine, vincristine, methotrexate, prednisone), ProMACE-MOPP
(methotrexate, doxorubicin, cyclophosphamide, etoposide, mechlorethamine, vincristine, procarbazine, prednisone), ProMACE-CytaBOM (prednisone, doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine, methotrexate, leucovorin), RVD
(lenalidomide, bortezomib, dexamethasone), Stanford V(doxorubicin, mechlorethamine, bleomycin, vinblastine, vincristine, etoposide, prednisone), Thal/Dex (thalidomide, dexamethasone), VAD
(vincristine, doxorubicin, dexamethasone), VAMP (vincristine, amethopterin, 6-mercaptopurine and prednisone, or vincristine, doxorubicin, methotrexate and prednisone, or vincristine, doxorubicin and methylprednisolone), VAPEC-B (vincristine, doxorubicin, prednisone, etoposide, cyclophosphamide, bleomycin), VD-PACE (bortezomib, dexamethasone, platinum agent, doxorubicin, cyclophosphamide, etoposide), and VTD-PACE (bortezomib, thalidomide, dexamethasone, platinum agent, doxorubicin, cyclophosphamide, etoposide).
[0039] In a specific embodiment, the combination chemotherapy that the human patient has failed is therapy with cyclophosphamide and prednisone. In a specific embodiment, the combination chemotherapy that the human patient has failed is a low-dose cyclophosphamide and prednisone regimen A low-dose cyclophosphamide and prednisone regimen is a regimen where less than about 900 mg/m2 per dose per day of intravenous cyclophosphamide is administered for less than 8 doses, and less than 2 mg/kg per dose, given twice per day, of oral prednisone is administered. In a specific embodiment, the combination chemotherapy is the low-dose cyclophosphamide and prednisone regimen described in Gross et al., 2012, Am J Transplant 12:3069-3075, as follows: a total of six cycles of therapy is given, and the cycles are given every 3 weeks; 600 mg/m2intravenous cyclophosphamide is given on day 1 of each cycle, and 1 mg/kg oral prednisone is given twice per day on days 1-5 of each cycle.
[0040] In a specific embodiment, the combination chemotherapy that the human patient has failed is therapy with cyclophosphamide and methylprednisolone. In a specific embodiment, the combination chemotherapy that the human patient has failed is a low-dose cyclophosphamide and methylprednisolone regimen. In a specific embodiment, the combination chemotherapy is the low-dose cyclophosphamide and methylprednisolone regimen is as described in Gross et al., 2012, Am J Transplant 12:3069-3075, as follows: a total of six cycles of therapy is given, and the cycles are given every 3 weeks; 600 mg/m2intravenous cyclophosphamide is given on day 1 of each cycle, and 0.8 mg/kg intravenous methylprednisolone is given every 12-hr on days 1-5 of each cycle.
[0041] In a specific embodiment, the combination chemotherapy that the human patient has failed is therapy with cyclophosphamide, prednisone, and methylprednisolone. In a specific embodiment, the combination chemotherapy that the human patient has failed is therapy with gemcitabine and vinorelbine. In a specific embodiment, the combination chemotherapy that the human patient has failed is therapy with methotrexate and temozolomide. In a specific embodiment, the combination chemotherapy that the human patient has failed is therapy with methotrexate, temozolomide and cytarabine. In a specific embodiment, the combination chemotherapy that the human patient has failed is therapy with prednisone and cyclophosphamide. In a specific embodiment, the combination chemotherapy that the human patient has failed is therapy with vincristine and cyclophosphamide. In a specific embodiment, the combination chemotherapy that the human patient has failed is therapy with doxorubicin, vincristine, prednisone, and methotrexate. In a specific embodiment, the combination chemotherapy that the human patient has failed is therapy with vinblastine, I
omustine, and cytarabine In a specific embodiment, the combination chemotherapy that the human patient has failed is COP. In a specific embodiment, the combination chemotherapy that the human patient has failed is BEACOPP. In a specific embodiment, the combination chemotherapy that the human patient has failed is CHOP. In a specific embodiment, the combination chemotherapy that the human patient has failed is therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, cytarabine, methotrexate, and dexamethasone. In a specific embodiment, the combination chemotherapy that the human patient has failed is IVAC. In a specific embodiment, the combination chemotherapy that the human patient has failed is ESHAP. In a specific embodiment, the combination chemotherapy that the human patient has failed is therapy with melphalan and dexamethasone. In a specific embodiment, the combination chemotherapy that the human patient has failed is ProMACE-CytaBOM. In a specific embodiment, the combination chemotherapy that the human patient has failed is CHOP. In a specific embodiment, the combination chemotherapy that the human patient has failed is DA-EPOCH.
omustine, and cytarabine In a specific embodiment, the combination chemotherapy that the human patient has failed is COP. In a specific embodiment, the combination chemotherapy that the human patient has failed is BEACOPP. In a specific embodiment, the combination chemotherapy that the human patient has failed is CHOP. In a specific embodiment, the combination chemotherapy that the human patient has failed is therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, cytarabine, methotrexate, and dexamethasone. In a specific embodiment, the combination chemotherapy that the human patient has failed is IVAC. In a specific embodiment, the combination chemotherapy that the human patient has failed is ESHAP. In a specific embodiment, the combination chemotherapy that the human patient has failed is therapy with melphalan and dexamethasone. In a specific embodiment, the combination chemotherapy that the human patient has failed is ProMACE-CytaBOM. In a specific embodiment, the combination chemotherapy that the human patient has failed is CHOP. In a specific embodiment, the combination chemotherapy that the human patient has failed is DA-EPOCH.
[0042] In a specific embodiment, the combination chemotherapy that the human patient has failed comprises any of the combinations of chemotherapeutic agents or chemotherapeutic regimens described above. In a specific embodiment, the combination chemotherapy that the human patient has failed consists essentially of any of the combinations of chemotherapeutic agents or chemotherapeutic regimens described above
[0043] In a specific embodiment, when the human patient has failed multiple different combination chemotherapies to treat the EBV-LPD, at least one of the multiple different combination chemotherapies is any of the combinations of chemotherapeutic agents or chemotherapeutic regimens described above. In a specific embodiment, when the human patient has failed multiple different combination chemotherapies to treat the EBV-LPD, at least one of the multiple different combination chemotherapies comprises any of the combinations of chemotherapeutic agents or chemotherapeutic regimens described above. In a specific embodiment, when the human patient has failed multiple different combination chemotherapies to treat the EBV-LPD, at least one of the multiple different combination chemotherapies consists essentially of any of the combinations of chemotherapeutic agents or chemotherapeutic regimens described above.
[0044] Radiation therapies use high-energy radiation to kill cancer cells by damaging their DNA. The radiation therapy that the human patient has failed, according to the invention, can be any known in the art for treatment of a LPD. Exemplary radiation therapies include, but are not limited to. conventional external beam radiation therapy, stereotactic radiation therapy, intensity-modulated radiation therapy, volumetric modulated arc therapy, particle therapy, auger therapy, brachytherapy, and radioisotope therapy.
[0045] In various embodiments, wherein the EBV-LPD is a disorder of cells of B cell lineage, in addition to failing therapy with any of the combination chemotherapies and/or radiation therapies described above, the human patient also has failed therapy with an anti-CD20 monoclonal antibody (alone or in combination with other therapies for the EBV-LPD). The anti-CD20 monoclonal antibody can be any known in the art. In specific embodiments, the anti-CD20 monoclonal antibody is a chimeric antibody or a humanized antibody. In specific embodiments, the anti-CD20 monoclonal antibody is a monovalent antibody or multivalent (e.g., bivalent) antibody. In certain embodiments, the anti-CD20 monoclonal antibody is a monospecific antibody or multispecific (e.g., bispecific) antibody. In specific embodiments, the anti-CD20 monoclonal antibody is conjugated with a cytotoxic agent;
alternatively, the anti-CD20 monoclonal antibody can be unconjugated. Exemplary anti-CD20 monoclonal antibodies include, but are not limited to: rituximab, obinutuzumab, ocrelizumab ofatumumab, ibritumomab tiuxetan, tositumomab, and veltuzumab. In a specific embodiment, the anti-CD20 monoclonal antibody is rituximab. In a specific embodiment, the human patient has failed R-CEOP (a therapy regimen with cyclophosphamide, etoposide, vincristine, prednisone, and rituximab). In a specific embodiment, the human patient has failed R-GEMOX (a therapy regimen with gemcitabine, oxaliplatin, and rituximab). In a specific embodiment, the human patient has failed R-COP (a therapy regimen with cyclophosphamide, vincristine, prednisone/prednisolone, and rituximab). In a specific embodiment, the human patient has failed R-CHOP (a therapy regimen with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab). In a specific embodiment, the human patient has failed a therapy with rituximab, cyclophosphamide and prednisone. In a specific embodiment, the human patient has failed a therapy with rituximab, cyclophosphamide and methylprednisolone. In a specific embodiment, the human patient has failed a treatment regimen described in Gross et al., 2012, Am J
Transplant 12:3069-3075, as follows: a total of six cycles of therapy is given, and the cycles are given every 3 weeks; 600 mg/m2intravenous cyclophosphamide is given on day 1 of each cycle for six cycles, 1 mg/kg oral prednisone is given twice a day (or 0.8 mg/kg intravenous methylprednisolone is given every 12-hr) on days 1-5 of each cycle for six cycles, and 375 mg/m2intravenous rituximab is given on days 1, 8, and 15 of each cycle for the first two cycles.
alternatively, the anti-CD20 monoclonal antibody can be unconjugated. Exemplary anti-CD20 monoclonal antibodies include, but are not limited to: rituximab, obinutuzumab, ocrelizumab ofatumumab, ibritumomab tiuxetan, tositumomab, and veltuzumab. In a specific embodiment, the anti-CD20 monoclonal antibody is rituximab. In a specific embodiment, the human patient has failed R-CEOP (a therapy regimen with cyclophosphamide, etoposide, vincristine, prednisone, and rituximab). In a specific embodiment, the human patient has failed R-GEMOX (a therapy regimen with gemcitabine, oxaliplatin, and rituximab). In a specific embodiment, the human patient has failed R-COP (a therapy regimen with cyclophosphamide, vincristine, prednisone/prednisolone, and rituximab). In a specific embodiment, the human patient has failed R-CHOP (a therapy regimen with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab). In a specific embodiment, the human patient has failed a therapy with rituximab, cyclophosphamide and prednisone. In a specific embodiment, the human patient has failed a therapy with rituximab, cyclophosphamide and methylprednisolone. In a specific embodiment, the human patient has failed a treatment regimen described in Gross et al., 2012, Am J
Transplant 12:3069-3075, as follows: a total of six cycles of therapy is given, and the cycles are given every 3 weeks; 600 mg/m2intravenous cyclophosphamide is given on day 1 of each cycle for six cycles, 1 mg/kg oral prednisone is given twice a day (or 0.8 mg/kg intravenous methylprednisolone is given every 12-hr) on days 1-5 of each cycle for six cycles, and 375 mg/m2intravenous rituximab is given on days 1, 8, and 15 of each cycle for the first two cycles.
[0046] As will be evident from the foregoing, where a human patient has failed both a combination chemotherapy to treat the EBV-LPD and a therapy with an anti-CD20 monoclonal antibody to treat the EBV-LPD, the combination chemotherapy and the therapy with the anti-CD20 monoclonal antibody can be combined in a single therapy regimen, or can be in separate therapy regimens administered over different time periods to the human patient.
4.2. A Population of Allogeneic T Cells Restricted by an Shared HLA Allele with the EBV-LPD
4.2. A Population of Allogeneic T Cells Restricted by an Shared HLA Allele with the EBV-LPD
[0047] According to the invention, a population of allogeneic T cells comprising EBV-specific T cells is administered to the human patient. The population of allogeneic T cells that is administered to the human patient is restricted by an HLA allele shared with cells of the EBV-LPD. In some embodiments, this HLA allele restriction is ensured by ascertaining the HLA
assignment of cells of the EBV-LPD, and selecting a population of allogeneic T
cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) restricted by an HLA allele of such cells. In other embodiments, when ascertaining the HLA
assignment of cells of the EBV-LPD is not possible and the human patient has not been the recipient of a transplant, this HLA allele restriction is ensured by ascertaining the HLA
assignment of the human patient (e.g., by using non-LPD cells or tissue from the human patient), and selecting a population of allogeneic T cells comprising EBV-specific T
cells (or a T cell line from which to derive the population of allogeneic T cells) restricted by an HLA allele of the human patient. In other embodiments, when ascertaining the 1-ILA assignment of cells of the EBV-LPD is not possible and the human patient has been the recipient of a transplant, this HLA
allele restriction is ensured by determining the origin of the EBV-LPD
(whether transplant donor or recipient (the human patient)), ascertaining the HLA assignment of the origin of the EBV-LPD (transplant donor or the human patient, as the case may be), and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) restricted by an HLA allele of the origin of the EBV-LPD.
When determining the origin of the EBV-LPD is not possible in such embodiments, this HLA
allele restriction is ensured by ascertaining the HLA assignment of both the human patient and the transplant donor, and selecting a population of allogeneic T cells comprising EBV-specific T
cells (or a T cell line from which to derive the population of allogeneic T
cells) restricted by an HLA allele shared by both the human patient and the transplant donor.
assignment of cells of the EBV-LPD, and selecting a population of allogeneic T
cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) restricted by an HLA allele of such cells. In other embodiments, when ascertaining the HLA
assignment of cells of the EBV-LPD is not possible and the human patient has not been the recipient of a transplant, this HLA allele restriction is ensured by ascertaining the HLA
assignment of the human patient (e.g., by using non-LPD cells or tissue from the human patient), and selecting a population of allogeneic T cells comprising EBV-specific T
cells (or a T cell line from which to derive the population of allogeneic T cells) restricted by an HLA allele of the human patient. In other embodiments, when ascertaining the 1-ILA assignment of cells of the EBV-LPD is not possible and the human patient has been the recipient of a transplant, this HLA
allele restriction is ensured by determining the origin of the EBV-LPD
(whether transplant donor or recipient (the human patient)), ascertaining the HLA assignment of the origin of the EBV-LPD (transplant donor or the human patient, as the case may be), and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) restricted by an HLA allele of the origin of the EBV-LPD.
When determining the origin of the EBV-LPD is not possible in such embodiments, this HLA
allele restriction is ensured by ascertaining the HLA assignment of both the human patient and the transplant donor, and selecting a population of allogeneic T cells comprising EBV-specific T
cells (or a T cell line from which to derive the population of allogeneic T
cells) restricted by an HLA allele shared by both the human patient and the transplant donor.
[0048] The origin of the EBV-LPD can be determined by any method known in the art, for example by analyzing variable tandem repeats (VTRs), a method that uses unique DNA
signature of small DNA sequences of different people to distinguish between the recipient and the donor of a transplant; or by looking for the presence or absence of chromosome Y if the donor and the recipient of a transplant are of different sexes, done by cytogenetics or by FISH
(fluorescence in situ hybridization).
signature of small DNA sequences of different people to distinguish between the recipient and the donor of a transplant; or by looking for the presence or absence of chromosome Y if the donor and the recipient of a transplant are of different sexes, done by cytogenetics or by FISH
(fluorescence in situ hybridization).
[0049] In some embodiments of ascertaining an HLA assignment, at least 4 HLA loci (preferably HLA-A, HLA-B, HLA-C, and HLA-DR) are typed. In some embodiments of ascertaining an HLA assignment, 4 HLA loci (preferably HLA-A, HLA-B, HLA-C, and HLA-DR) are typed. In some embodiments of ascertaining an HLA assignment, 6 HLA
loci are typed.
In some embodiments of ascertaining an HLA assignment, 8 HLA loci are typed
loci are typed.
In some embodiments of ascertaining an HLA assignment, 8 HLA loci are typed
[0050] In specific embodiments, in addition to being restricted by an HLA
allele shared with the EBV-LPD, the population of allogeneic T cells comprising EBV-specific T cells shares at least 2 out of 8 HLA alleles (for example, two HLA-A alleles, two HLA-B
alleles, two HLA-C
alleles, and two TrILA-DR alleles) with cells of the EBV-LPD. In some embodiments, this sharing is ensured by ascertaining the HLA assignment of cells of the EBV-LPD, and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) that shares at least 2 out of 8 HLA alleles with such cells. In other embodiments, when ascertaining the HLA assignment of cells of the EBV-LPD is not possible and the human patient has not been the recipient of a transplant, this sharing is ensured by ascertaining the HLA assignment of the human patient (e.g., by using non-LPD cells or tissue from the human patient), and selecting a population of allogeneic T
cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) that shares at least 2 out of 8 HLA alleles with the human patient. In other embodiments, when ascertaining the HLA assignment of cells of the EBV-LPD is not possible and the human patient has been the recipient of a transplant, this sharing is ensured by determining the origin of the EBV-LPD (whether transplant donor or recipient (the human patient)), ascertaining the HLA
assignment of the origin of the EBV-LPD (transplant donor or the human patient, as the case may be), and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T
cell line from which to derive the population of allogeneic T cells) that shares at least 2 out of 8 HLA alleles with the origin of the EBV-LPD. When determining the origin of the EBV-LPD is not possible in such embodiments, this is ensured by ascertaining the HLA
assignment of both the human patient and the transplant donor, and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) that shares at least 2 out of 8 HLA alleles with both the human patient and the transplant donor.
allele shared with the EBV-LPD, the population of allogeneic T cells comprising EBV-specific T cells shares at least 2 out of 8 HLA alleles (for example, two HLA-A alleles, two HLA-B
alleles, two HLA-C
alleles, and two TrILA-DR alleles) with cells of the EBV-LPD. In some embodiments, this sharing is ensured by ascertaining the HLA assignment of cells of the EBV-LPD, and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) that shares at least 2 out of 8 HLA alleles with such cells. In other embodiments, when ascertaining the HLA assignment of cells of the EBV-LPD is not possible and the human patient has not been the recipient of a transplant, this sharing is ensured by ascertaining the HLA assignment of the human patient (e.g., by using non-LPD cells or tissue from the human patient), and selecting a population of allogeneic T
cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) that shares at least 2 out of 8 HLA alleles with the human patient. In other embodiments, when ascertaining the HLA assignment of cells of the EBV-LPD is not possible and the human patient has been the recipient of a transplant, this sharing is ensured by determining the origin of the EBV-LPD (whether transplant donor or recipient (the human patient)), ascertaining the HLA
assignment of the origin of the EBV-LPD (transplant donor or the human patient, as the case may be), and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T
cell line from which to derive the population of allogeneic T cells) that shares at least 2 out of 8 HLA alleles with the origin of the EBV-LPD. When determining the origin of the EBV-LPD is not possible in such embodiments, this is ensured by ascertaining the HLA
assignment of both the human patient and the transplant donor, and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) that shares at least 2 out of 8 HLA alleles with both the human patient and the transplant donor.
[0051] The HLA assignment (i.e., the HLA loci type) can be ascertained (i.e., typed) by any method known in the art. Non-limiting exemplary methods for ascertaining the HLA
assignment can be found in ASHI Laboratory Manual, Edition 4.2 (2003), American Society for Histocompatibility and Immunogenetics; ASHI Laboratory Manual, Supplements 1 (2006) and 2 (2007), American Society for Histocompatibility and Immunogenetics; Hurley, "DNA-based typing of HLA for transplantation." in Leffell et al., eds., 1997, Handbook of Human Immunology, Boca Raton: CRC Press; Dunn, 2011, Int J Immunogenet 38:463-473;
Erlich, 2012, Tissue Antigens, 80:1-11; Bontadini, 2012, Methods, 56:471-476; and Lange et al., 2014, BMC Genomics 15: 63.
assignment can be found in ASHI Laboratory Manual, Edition 4.2 (2003), American Society for Histocompatibility and Immunogenetics; ASHI Laboratory Manual, Supplements 1 (2006) and 2 (2007), American Society for Histocompatibility and Immunogenetics; Hurley, "DNA-based typing of HLA for transplantation." in Leffell et al., eds., 1997, Handbook of Human Immunology, Boca Raton: CRC Press; Dunn, 2011, Int J Immunogenet 38:463-473;
Erlich, 2012, Tissue Antigens, 80:1-11; Bontadini, 2012, Methods, 56:471-476; and Lange et al., 2014, BMC Genomics 15: 63.
[0052] In general, high-resolution typing is preferable for HLA typing. The high-resolution typing can be performed by any method known in the art, for example, as described in ASHI Laboratory Manual, Edition 4.2 (2003), American Society for Histocompatibility and Immunogenetics; ASHI Laboratory Manual, Supplements 1 (2006) and 2 (2007), American Society for Histocompatibility and Immunogenetics; Flomenberg et al., Blood, 104:1923-1930;
Kogler et al., 2005, Bone Marrow Transplant, 36:1033-1041; Lee et al., 2007, Blood 110:4576-4583; Erlich, 2012, Tissue Antigens, 80:1-11; Lank et al., 2012, BMC Genomics 13:378; or Gabriel et al., 2014, Tissue Antigens, 83:65-75. In specific embodiments, the methods of treating an EBV-LPD as described herein further comprise prior to the administering step a step of ascertaining at least one HLA allele of cells of the EBV-LPD by high-resolution typing.
Kogler et al., 2005, Bone Marrow Transplant, 36:1033-1041; Lee et al., 2007, Blood 110:4576-4583; Erlich, 2012, Tissue Antigens, 80:1-11; Lank et al., 2012, BMC Genomics 13:378; or Gabriel et al., 2014, Tissue Antigens, 83:65-75. In specific embodiments, the methods of treating an EBV-LPD as described herein further comprise prior to the administering step a step of ascertaining at least one HLA allele of cells of the EBV-LPD by high-resolution typing.
[0053] The HLA allele by which the population of allogeneic T cells is restricted can be determined by any method known in the art, for example, as described in Trivedi et al., 2005, Blood 105:2793-2801; Barker et al., 2010, Blood 116:5045-5049; Hasan et al., 2009, J Immunol, 183:2837-2850; or Doubrovina et al., 2012, Blood 120:1633-1646.
[0054] Preferably, the HLA allele by which the population of allogeneic T
cells is restricted and is shared with cells of the EBV-LPD is defined by high-resolution typing.
Preferably, the HLA alleles that are shared between the population of allogeneic T cells and cells of the EBV-LPD are defined by high-resolution typing. Most preferably, both the HLA allele by which the population of allogeneic T cells is restricted and is shared with cells of the EBV-LPD, and the HLA alleles that are shared between the population of allogeneic T
cells and cells of the EBV-LPD are defined by high-resolution typing.
4.3. Obtaining or Generating a Population of Allogeneic T Cells Comprising EBV-specific T Cells
cells is restricted and is shared with cells of the EBV-LPD is defined by high-resolution typing.
Preferably, the HLA alleles that are shared between the population of allogeneic T cells and cells of the EBV-LPD are defined by high-resolution typing. Most preferably, both the HLA allele by which the population of allogeneic T cells is restricted and is shared with cells of the EBV-LPD, and the HLA alleles that are shared between the population of allogeneic T
cells and cells of the EBV-LPD are defined by high-resolution typing.
4.3. Obtaining or Generating a Population of Allogeneic T Cells Comprising EBV-specific T Cells
[0055] The population of allogeneic T cells comprising EBV-specific T cells that is administered to the human patient can be generated by a method known in the art, or can be selected from a preexisting bank (collection) of cryopreserved T cell lines (each T cell line comprising EBV-specific T cells) generated by a method known in the art, and thawed and preferably expanded prior to administration. Preferably, unique identifier for each T cell line in the bank is associated with information as to which HLA allele(s) the respective T cell line is restricted, and optionally also information as to the HLA assignment of the respective T cell line.
The population of allogeneic T cells and the T cell lines in the bank are preferably obtained or generated by methods described below.
The population of allogeneic T cells and the T cell lines in the bank are preferably obtained or generated by methods described below.
[0056] In various embodiments, the methods of treating an EBV-LPD further comprise prior to the administering step a step of obtaining the population of allogeneic T cells.
[0057] In specific embodiments, the step of obtaining the population of allogeneic T cells comprises fluorescence activated cell sorting for EBV-positive T cells from a population of blood cells. In a specific embodiment, the population of blood cells are peripheral blood mononuclear cells (PM/Ws) isolated from a blood sample(s) obtained from a human donor. The fluorescence activated cell sorting can be performed by any method known in the art, which normally involves staining the population of blood cells with an antibody that recognizes at least one EBV antigen before the sorting step.
[0058] In specific embodiments, the step of obtaining the population of allogeneic T cells comprises generating the population of allogeneic T cells in vitro The population of allogeneic T cells can be generated in vitro by any method known in the art. Non-limiting exemplary methods of generating the population of allogeneic T cells can be found in Koehne et al., 2000, Blood 96:109-117; Koehne, et al., 2002, Blood 99:1730-1740; O'Reilly et al., 2007, Immunol Res 38:237-250; Barker et al., 2010, Blood 116:5045-5049; 0' Reilly et al., 2011, Best Practice & Research Clinical Haematology 24:381-391; and Doubrovina et al., 2012, Blood 119:2644-2656.
[0059] In certain embodiments, the step of generating the population of allogeneic T cells in vitro comprises sensitizing (i.e., stimulating) allogeneic T cells to one or more EBV antigens so as to produce EBV-specific T cells. The allogeneic T cells that are used for generating the population of allogeneic T cells in vitro can be isolated from the donor of the allogeneic T cells by any method known in the art, for example, as described in Koehne, et al., 2002, Blood 99:1730-1740; O'Reilly et al., 2007, Immunol Res. 38:237-250; or Barker et al., 2010, Blood 116:5045-5049. In a specific embodiment, the allogeneic T cells are enriched from peripheral blood lymphocytes separated from PBMCs of the donor of the allogeneic T cells.
In a further specific embodiment, T cells are enriched from peripheral blood lymphocytes separated from PBMCs of the donor of the allogeneic T cells by depletion of adherent monocytes followed by depletion of natural killer cells. In various embodiments, the allogeneic T
cells are cryopreserved for storage. In a specific embodiment, wherein the allogeneic T
cells are cryopreserved, the cryopreserved allogeneic T cells are thawed and expanded in vitro before sensitizing. In a specific embodiment, wherein the allogeneic T cells are cryopreserved, the cryopreserved allogeneic T cells are thawed and then sensitized, but not expanded in vitro before sensitizing, and then optionally expanded. In specific embodiments, the allogeneic T cells are cryopreserved after sensitizing (sensitizing produces the EBV-specific T
cells). In a specific embodiment, wherein the allogeneic T cells are cryopreserved after sensitizing, the cryopreserved allogeneic T cells are thawed and expanded in vitro to produce the population of allogeneic T cells comprising EBV-specific T cells. In another specific embodiment, wherein the allogeneic T cells are cryopreserved after sensitizing, the cryopreserved allogeneic T cells are thawed but not expanded in vitro to produce the population of allogeneic T
cells comprising EBV-specific T cells. In other various embodiments, the allogeneic T cells are not cryopreserved. In a specific embodiment, wherein the allogeneic T cells are not cryopreserved, the allogeneic T cells are expanded in vitro before sensitizing. In a specific embodiment, wherein the allogeneic T cells are not cryopreserved, the allogeneic T cells are not expanded in vitro before sensitizing. In specific embodiments, the step of generating the population of allogeneic T cells in vitro further comprises, after sensitizing, cryopreserving the allogeneic T
cells.
In a further specific embodiment, T cells are enriched from peripheral blood lymphocytes separated from PBMCs of the donor of the allogeneic T cells by depletion of adherent monocytes followed by depletion of natural killer cells. In various embodiments, the allogeneic T
cells are cryopreserved for storage. In a specific embodiment, wherein the allogeneic T
cells are cryopreserved, the cryopreserved allogeneic T cells are thawed and expanded in vitro before sensitizing. In a specific embodiment, wherein the allogeneic T cells are cryopreserved, the cryopreserved allogeneic T cells are thawed and then sensitized, but not expanded in vitro before sensitizing, and then optionally expanded. In specific embodiments, the allogeneic T cells are cryopreserved after sensitizing (sensitizing produces the EBV-specific T
cells). In a specific embodiment, wherein the allogeneic T cells are cryopreserved after sensitizing, the cryopreserved allogeneic T cells are thawed and expanded in vitro to produce the population of allogeneic T cells comprising EBV-specific T cells. In another specific embodiment, wherein the allogeneic T cells are cryopreserved after sensitizing, the cryopreserved allogeneic T cells are thawed but not expanded in vitro to produce the population of allogeneic T
cells comprising EBV-specific T cells. In other various embodiments, the allogeneic T cells are not cryopreserved. In a specific embodiment, wherein the allogeneic T cells are not cryopreserved, the allogeneic T cells are expanded in vitro before sensitizing. In a specific embodiment, wherein the allogeneic T cells are not cryopreserved, the allogeneic T cells are not expanded in vitro before sensitizing. In specific embodiments, the step of generating the population of allogeneic T cells in vitro further comprises, after sensitizing, cryopreserving the allogeneic T
cells.
[0060] In specific embodiments, the methods of treating an EBV-LPD as described herein further comprise, before the administering step, steps of thawing cryopreserved EBV-antigen sensitized allogeneic T cells, and expanding the allogeneic T cells in vitro, to produce the population of allogeneic T cells.
[0061] In certain embodiments, the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using EBV-transformed B
cells (i.e., contacting allogeneic T cells with EBV-transformed B cells). B cells transformed by EBV
strain B95.8, for example, can be used for this purpose.
cells (i.e., contacting allogeneic T cells with EBV-transformed B cells). B cells transformed by EBV
strain B95.8, for example, can be used for this purpose.
[0062] In certain embodiments, the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using dendritic cells (preferably, the dendritic cells are derived from the donor of allogeneic T cells). In specific embodiments, the step of sensitizing allogeneic T cells using dendritic cells comprises loading the dendritic cells with at least one immunogenic peptide derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T cells using dendritic cells comprises loading the dendritic cells with a pool of overlapping peptides derived from one or more EBV antigens.
[0063] In certain embodiments, the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using cytokine-activated monocytes (preferably, the cytokine-activated monocytes are derived from the donor of allogeneic T
cells). In specific embodiments, the step of sensitizing allogeneic T cells using cytokine-activated monocytes comprises loading the cytokine-activated monocytes with at least one immunogenic peptide derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T cells using cytokine-activated monocytes comprises loading the cytokine-activated monocytes with a pool of overlapping peptides derived from one or more EBV
antigens.
cells). In specific embodiments, the step of sensitizing allogeneic T cells using cytokine-activated monocytes comprises loading the cytokine-activated monocytes with at least one immunogenic peptide derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T cells using cytokine-activated monocytes comprises loading the cytokine-activated monocytes with a pool of overlapping peptides derived from one or more EBV
antigens.
[0064] In certain embodiments, the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using peripheral blood mononuclear cells (preferably, the peripheral blood mononuclear cells are derived from the donor of allogeneic T
cells). In specific embodiments, the step of sensitizing allogeneic T cells using peripheral blood mononuclear cells comprises loading the peripheral blood mononuclear cells with at least one immunogenic peptide derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T cells using peripheral blood mononuclear cells comprises loading the peripheral blood mononuclear cells with a pool of overlapping peptides derived from one or more EBV antigens
cells). In specific embodiments, the step of sensitizing allogeneic T cells using peripheral blood mononuclear cells comprises loading the peripheral blood mononuclear cells with at least one immunogenic peptide derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T cells using peripheral blood mononuclear cells comprises loading the peripheral blood mononuclear cells with a pool of overlapping peptides derived from one or more EBV antigens
[0065] In certain embodiments, the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using artificial antigen-presenting cells (AAPCs). In specific embodiments, the step of sensitizing allogeneic T cells using AAPCs comprises loading the AAPCs with at least one immunogenic peptide derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T
cells using AAPCs comprises loading the AAPCs with a pool of overlapping peptides derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T
cells using AAPCs comprises engineering the AAPCs to express at least one immunogenic EBV
peptide or protein in the AAPCs.
cells using AAPCs comprises loading the AAPCs with a pool of overlapping peptides derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T
cells using AAPCs comprises engineering the AAPCs to express at least one immunogenic EBV
peptide or protein in the AAPCs.
[0066] In various embodiments, the pool of peptides is a pool of overlapping peptides spanning an antigen of EBV. In various embodiments, the pool of peptides is a pool of overlapping peptides spanning more than one antigen of EBV. In a specific embodiment, the pool of overlapping peptides is a pool of overlapping pentadecapeptides.
[0067] In specific embodiments, the population of allogeneic T cells has been cryopreserved for storage before administering. In specific embodiments, the population of allogeneic T cells has not been cryopreserved for storage before administering. In certain embodiments, the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of thawing a cryopreserved form of the population of allogeneic T
cells.
cells.
[0068] In various embodiments, the population of allogeneic T cells is derived from a T
cell line. In specific embodiments, the T cell line has been cryopreserved for storage before administering. In specific embodiments, the T cell line has not been cryopreserved for storage before administering. In some embodiments, the T cell line has been expanded in vitro to derive the population of allogeneic T cells. In other embodiments, the T cell line has not been expanded in vitro to derive the population of allogeneic T cells. The T cell line can be sensitized to one or more EBV antigens (so as to produce EBV-specific T cells, for example, by a sensitizing step described above) before or after cryopreservation (if the T
cell line has been cryopreserved), and before or after expanding in vitro (if the T cell line has been expanded in vitro). In certain embodiments, the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of selecting the T cell line from a bank of a plurality of cryopreserved T cell lines (preferably each comprising EBV-specific T cells).
Preferably, unique identifier for each T cell line in the bank is associated with information as to which HLA allele(s) the respective T cell line is restricted, and optionally also information as to the FILA assignment of the respective T cell line. In certain embodiments, the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of thawing a cryopreserved form of the T cell line. In specific embodiments, the methods of treating an EBV-LPD as described herein further comprises, before the administering step, a step of expanding the T cell line (for example, after thawing a cryopreserved form of the T cell line) in vitro. The T cell line and the plurality of cryopreserved T cell lines can be generated by any method known in the art, for example, as described in Koehne, et al., 2002, Blood 99:1730-1740;
O'Reilly et al., 2007, Immunol Res. 38:237-250; Barker et al., 2010, Blood 116:5045-5049, or as describe above for generating the population of allogeneic T cells in vitro.
cell line. In specific embodiments, the T cell line has been cryopreserved for storage before administering. In specific embodiments, the T cell line has not been cryopreserved for storage before administering. In some embodiments, the T cell line has been expanded in vitro to derive the population of allogeneic T cells. In other embodiments, the T cell line has not been expanded in vitro to derive the population of allogeneic T cells. The T cell line can be sensitized to one or more EBV antigens (so as to produce EBV-specific T cells, for example, by a sensitizing step described above) before or after cryopreservation (if the T
cell line has been cryopreserved), and before or after expanding in vitro (if the T cell line has been expanded in vitro). In certain embodiments, the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of selecting the T cell line from a bank of a plurality of cryopreserved T cell lines (preferably each comprising EBV-specific T cells).
Preferably, unique identifier for each T cell line in the bank is associated with information as to which HLA allele(s) the respective T cell line is restricted, and optionally also information as to the FILA assignment of the respective T cell line. In certain embodiments, the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of thawing a cryopreserved form of the T cell line. In specific embodiments, the methods of treating an EBV-LPD as described herein further comprises, before the administering step, a step of expanding the T cell line (for example, after thawing a cryopreserved form of the T cell line) in vitro. The T cell line and the plurality of cryopreserved T cell lines can be generated by any method known in the art, for example, as described in Koehne, et al., 2002, Blood 99:1730-1740;
O'Reilly et al., 2007, Immunol Res. 38:237-250; Barker et al., 2010, Blood 116:5045-5049, or as describe above for generating the population of allogeneic T cells in vitro.
[0069] The population of allogeneic T cells comprising EBV-specific T cells that is administered to the human patient comprises CD8+ T cells, and in a specific embodiment also comprises CD4+ T cells.
[0070] The EBV-specific T cells administered in accordance with the methods described herein recognize at least one antigen of EBV. In specific embodiments, the EBV-specific T cells administered in accordance with the methods described herein recognizes an EBV
antigen that is EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1 or LMP2.
4.4. Administration and Dosage
antigen that is EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1 or LMP2.
4.4. Administration and Dosage
[0071] The route of administration of the population of allogeneic T cells and the amount to be administered to the human patient can be determined based on the condition of the human patient and the knowledge of the physician. Generally, the administration is intravenous.
[0072] In certain embodiments, the administering is by infusion of the population of allogeneic T cells. In some embodiments, the infusion is bolus intravenous infusion. In certain embodiments, the administering comprises administering at least about 1 x 105 T cells of the population of allogeneic T cells per kg per dose per week to the human patient. In some embodiments, the administering comprises administering about 1 x 106 to about 2 x 106T cells of the population of allogeneic T cells per kg per dose per week to the human patient. In a specific embodiment, the administering comprises administering about 1 x 106 T cells of the population of allogeneic T cells per kg per dose per week to the human patient. In another specific embodiment, the administering comprises administering about 2 x 106T cells of the population of allogeneic T cells per kg per dose per week to the human patient.
[0073] In certain embodiments, the methods of treating an EBV-LPD as described herein comprise administering at least 2 doses of the population of allogeneic T
cells to the human patient. In specific embodiments, the methods of treating an EBV-LPD as described herein comprise administering 2, 3, 4, 5, or 6 doses of the population of allogeneic T cells to the human patient.
cells to the human patient. In specific embodiments, the methods of treating an EBV-LPD as described herein comprise administering 2, 3, 4, 5, or 6 doses of the population of allogeneic T cells to the human patient.
[0074] In certain embodiments, the methods of treating an EBV-LPD as described herein comprise administering a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period during which no dose of the population of allogeneic T cells is administered, followed by a second cycle of the one dose per week of the population of allogeneic T cells for 3 consecutive weeks. In certain embodiments, the methods of treating an EBV-LPD as described herein comprise administering at least two cycles of one dose per week of the population of allogeneic T cells for 3 consecutive weeks, each cycle separated by a washout period during which no dose of the population of allogeneic T cells is administered. In specific embodiments, the methods of treating an EBV-LPD as described herein comprise administering two, three, four, five, or six cycles of one dose per week of the population of allogeneic T cells for 3 consecutive weeks, each cycle separated by a washout period during which no dose of the population of allogeneic T cells is administered. In a specific embodiment, the washout period is about three weeks. Preferably, an additional cycle is administered only when the previous cycle has not exhibited toxicity (for example, no grade 3-5 serious adverse events, graded according to NCI CTCAE 4.0).
[0075] In certain embodiments, a first dosage regimen described herein is carried out for a first period of time, followed by a second and different dosage regimen described herein that is carried out for a second period of time, wherein the first period of time and the second period of time are optionally separated by a washout period (for example, about three weeks). Preferably, the second dosage regimen is carried out only when the first dosage regimen has not exhibited toxicity (for example, no grade 3-5 serious adverse events, graded according to NCI CTCAE
4.0).
4.0).
[0076] The term "about" shall be construed so as to allow normal variation.
4.5. Serial Treatment with Different T Cell Populations
4.5. Serial Treatment with Different T Cell Populations
[0077] In certain embodiments, the methods of treating an EBV-LPD further comprise, after administering to the human patient the population of allogeneic T cells, administering to the human patient a second population of allogeneic T cells comprising EBV-specific T cells;
wherein the second population of allogeneic T cells is restricted by a different HLA allele shared with cells of the EBV-LPD. The second population of allogeneic T cells can be administered by any route and any dosage/administration regimen as described in Section 4.4.
In a specific embodiment, the methods of treating an EBV-LPD comprise administering a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period during which no dose of the population of allogeneic T cells is administered, followed by a second cycle of one dose per week of the second population of allogeneic T cells for 3 consecutive weeks. In a further specific embodiment, the washout period is about three weeks.
wherein the second population of allogeneic T cells is restricted by a different HLA allele shared with cells of the EBV-LPD. The second population of allogeneic T cells can be administered by any route and any dosage/administration regimen as described in Section 4.4.
In a specific embodiment, the methods of treating an EBV-LPD comprise administering a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period during which no dose of the population of allogeneic T cells is administered, followed by a second cycle of one dose per week of the second population of allogeneic T cells for 3 consecutive weeks. In a further specific embodiment, the washout period is about three weeks.
[0078] In certain embodiments, the human patient has no response, an incomplete response, or a suboptimal response (i.e., the human patient may still have a substantial benefit from continuing treatment, but has reduced chances of optimal long-term outcomes) after administering the population of allogeneic T cells and prior to administering the second population of allogeneic T cells.
[0079] In specific embodiments, two populations of allogeneic EBV-specific T cells that are each restricted by a different HLA allele shared with cells of the EBV-LPD
are administered serially. In specific embodiments, three populations of allogeneic EBV-specific T cells that are each restricted by a different HLA allele shared with cells of the EBV-LPD are administered serially. In specific embodiments, four populations of allogeneic EBV-specific T cells that are each restricted by a different HLA allele shared with cells of the EBV-LPD are administered serially. In specific embodiments, more than four populations of allogeneic EBV-specific T cells that are each restricted by a different HLA allele shared with cells of the EBV-LPD are administered serially.
4.6. Patients
are administered serially. In specific embodiments, three populations of allogeneic EBV-specific T cells that are each restricted by a different HLA allele shared with cells of the EBV-LPD are administered serially. In specific embodiments, four populations of allogeneic EBV-specific T cells that are each restricted by a different HLA allele shared with cells of the EBV-LPD are administered serially. In specific embodiments, more than four populations of allogeneic EBV-specific T cells that are each restricted by a different HLA allele shared with cells of the EBV-LPD are administered serially.
4.6. Patients
[0080] The human patient can be anyone who has an EBV-LPD and who has failed combination chemotherapy to treat the EBV-LPD (and in some embodiments, also has failed therapy with an anti-CD20 monoclonal antibody) and/or radiation therapy (and in some embodiments, also has failed therapy with an anti-CD20 monoclonal antibody).
[0081] LPDs are conditions in which lymphocytes are excessively proliferating, and can occur in immunocompromised patients. EBV-LPDs that can be treated by the methods described herein include, but are not limited to, B-cell hyperplasia, B-cell lymphoma (for example, diffuse large B-cell lymphoma), T-cell lymphoma, polymorphic or monomorphic EBV-LPD, EBY-positive Hodgkin's lymphoma, Burkitt lymphoma, autoimmune lymphoproliferative syndrome, and mixed PTLD (post-transplant lymphoproliferative disorder). In a specific embodiment, the EBV-LPD is an EBV-positive lymphoma (for example, and EBV-positive B-cell lymphoma). In specific embodiments, the EBV-LPD treated in accordance with a method described herein is present in the central nervous system of the human patient. In a specific embodiment, the EBV-LPD treated in accordance with a method described herein is present in the brain of the human patient.
[0082] In various embodiments, the human patient has been immunocompromised. In various embodiments, the human patient has been the recipient of a transplant.
In some embodiments, the human patient has been the recipient of a solid organ transplant from a transplant donor. In some embodiments, the human patient has been the recipient of multiple organ transplants (for example, heart and lung transplants, or kidney and pancreas transplants).
The solid organ transplant can be, but is not limited to, a kidney transplant, a liver transplant, a heart transplant, an intestinal transplant, a pancreas transplant, a lung transplant, or a combination thereof. In a specific embodiment, the solid organ transplant is a kidney transplant.
In another specific embodiment, the solid organ transplant is a liver transplant. In some embodiments, the human patient has been the recipient of a hematopoietic stem cell transplant (HSCT) from a transplant donor. The HSCT can be a bone marrow transplant, a peripheral blood stem cell transplant, or a cord blood transplant. In specific embodiments, the population of allogeneic T cells is derived from a donor other than the transplant donor. In other specific embodiments, the population of allogeneic T cells is derived from the transplant donor. In various embodiments, the human patient has not been the recipient of a transplant.
In some embodiments, the human patient has been the recipient of a solid organ transplant from a transplant donor. In some embodiments, the human patient has been the recipient of multiple organ transplants (for example, heart and lung transplants, or kidney and pancreas transplants).
The solid organ transplant can be, but is not limited to, a kidney transplant, a liver transplant, a heart transplant, an intestinal transplant, a pancreas transplant, a lung transplant, or a combination thereof. In a specific embodiment, the solid organ transplant is a kidney transplant.
In another specific embodiment, the solid organ transplant is a liver transplant. In some embodiments, the human patient has been the recipient of a hematopoietic stem cell transplant (HSCT) from a transplant donor. The HSCT can be a bone marrow transplant, a peripheral blood stem cell transplant, or a cord blood transplant. In specific embodiments, the population of allogeneic T cells is derived from a donor other than the transplant donor. In other specific embodiments, the population of allogeneic T cells is derived from the transplant donor. In various embodiments, the human patient has not been the recipient of a transplant.
[0083] In specific embodiments, the human patient is a patient infected with HIV.
[0084] In specific embodiments, the human patient has received immunosuppressant therapy (for example, after solid organ transplant). In a particular aspect of such specific embodiments, the dosage of the immunosuppressant given to the human patient has been reduced, and the human patient has failed the therapy for the EBV-LPD of reducing the immunosuppressant dosage.
[0085] In specific embodiments, the human patient has a primary immunodeficiency (for example, a genetic disorder that has caused immunodeficiency).
[0086] In other embodiments, the human patient has not been immunocompromised.
5. EXAMPLE
5. EXAMPLE
[0087] Certain embodiments provided herein are illustrated by the following non-limiting example, which demonstrates that the therapy with a population of allogeneic T
cells comprising EBV-specific T cells according to the invention is effective in treating EBV-LPDs that are resistant to combination chemotherapy or radiation therapy, and are also resistant to therapy with rituximab, as a later line therapy with low toxicity.
5.1. Example
cells comprising EBV-specific T cells according to the invention is effective in treating EBV-LPDs that are resistant to combination chemotherapy or radiation therapy, and are also resistant to therapy with rituximab, as a later line therapy with low toxicity.
5.1. Example
[0088] Eleven recipients of solid organ transplant (SOT) were referred to Memorial Sloan Kettering Cancer Center for treatment of EBV-LPD in the form of a lymphoma after prior systemic chemotherapy. All had previously received rituximab and at least two prior combination chemotherapy regimens. Nine were referred for either incomplete response (3) or progression of disease (6) while receiving combination chemotherapy regimens, while two were referred at the time of relapse after prior combination chemotherapy. Thus, all 11 patients had failed combination chemotherapy for the EBV-LPD.
[0089] Where possible the lymphoma was assessed for origin (SOT donor vs host). In instances where this was not possible, high resolution HLA testing of SOT
donor tissue was performed for at least one allele with the goal of finding a line that was restricted by HLA alleles on both the host and the solid organ donor.
donor tissue was performed for at least one allele with the goal of finding a line that was restricted by HLA alleles on both the host and the solid organ donor.
[0090] T cell lines were selected from a bank of allogeneic T cell lines (each comprising EBV-specific T cells) that shared at least 2/8 HLA alleles (A, B, C and DR) at high resolution with the patient and HLA restricted in recognition of EBV through an allele known to be expressed by the lymphoma or by alleles expressed by both the host and the solid organ donor tissue.
[0091] Patients received 2 x 106 T cells/kg/dose for 3 weekly doses.
Patients could receive additional cycles of cells if they had no toxicity related to the T
cell therapy (no Grade 3-serious adverse events, graded according to NCI CTCAE 4.0) 5 weeks after the start of therapy. Patients could receive subsequent cycles of cells from different allogeneic T cell lines, preferably restricted by different HLA alleles.
Patients could receive additional cycles of cells if they had no toxicity related to the T
cell therapy (no Grade 3-serious adverse events, graded according to NCI CTCAE 4.0) 5 weeks after the start of therapy. Patients could receive subsequent cycles of cells from different allogeneic T cell lines, preferably restricted by different HLA alleles.
[0092] Some of the patients received additional cycles of T cells, and some received additional cycles of T cells from at least one different allogeneic T cell line restricted by a different HLA allele.
[0093] Seven of the eleven patients responded to therapy. One who responded received subsequent systemic chemotherapy for recurrence of low grade disease to which she did not fully respond and was again in partial remission after subsequent T cell therapy.
Two out of the seven who responded received subsequent rituximab treatment and re-treatment with EBV-specific T
cells. One patient with a complete response died of failure of the transplanted organ that had predated cellular therapy. Three patients presented with high disease burden that was rapidly progressive at initiation of therapy and progressed during the first cycle of T cell therapies and these patients did not receive subsequent cycles of T cell therapy.
Two out of the seven who responded received subsequent rituximab treatment and re-treatment with EBV-specific T
cells. One patient with a complete response died of failure of the transplanted organ that had predated cellular therapy. Three patients presented with high disease burden that was rapidly progressive at initiation of therapy and progressed during the first cycle of T cell therapies and these patients did not receive subsequent cycles of T cell therapy.
[0094] In addition, one patient with CNS (central nervous system) involvement of EBV-LPD was treated with incomplete response to rituximab and radiation therapy alone. This patient continued rituximab and started radiation concomitant to his first cycle of treatment with EBV-specific T cells. EBV-LPDs present in the brain (i.e., with brain involvement) are especially difficult to treat by chemotherapies and radiation therapies, because many chemotherapeutic agents cannot cross the blood-brain barrier, and radiation therapies normally cause damages to the brain; however a partial remission was achieved with the patient with brain involvement.
That first cycle of T cell therapy was graded NE (not evaluable) and he had a slight response at the end. After subsequent cycles he had near resolution while receiving EBV-specific T cells as the only therapy for the EBV-LPD.
That first cycle of T cell therapy was graded NE (not evaluable) and he had a slight response at the end. After subsequent cycles he had near resolution while receiving EBV-specific T cells as the only therapy for the EBV-LPD.
[0095] The T cell treatments exhibited low toxicity.
[0096] The fact that the methods described herein can effectively treat EBV-LPDs in patients who have been solid organ transplant recipients is especially remarkable, considering that the population of allogeneic T cells administered usually can only persist for a short period of time (in general shorter than in hematopoietic stem cell transplant (HSCT) recipients), due to rejection of the administered allogeneic T cells by the patient's relatively intact immune system (relative to patients who are recipients of HSCT).
[0097] Some of the therapy regimens that the patients have received are listed below in Table 1.
[0098] Table 1. Therapy Regimens 1. 6 cycles ANHL0221 (cyclophosphamide, prednisone, methylnisolone +
rituximab); 2. 6 cycles gemcitabine/vinorelbine 1. 5 cycles R-CEOP 2. R-GEMOX 3. rituximab + bortezomib HD methotrexate & temozolomide w/ rituximab; cytarabine 1. rituximab/prednisone/ cyclophosphamide) 2.
vincristine/rituximab/cyclophosphamide 1. ANHL0131 (doxorubicin, vincristine, prednisone, IT methotrexate) 2.
vinblastine, CCNU, and ARA-C 3. ANHL01P1 (COP-R) 4. BEACOPP
1. Cyclophosphamide, prednisone, rituximab per ANHL0221 6 cycles R-CHOP; IT cytarabine; 5 day course IT methotrexate, ara-C, dexamethasone 3 cycles IVAC start 1. tonsillectomy/adenoidectomy 2. ANHL 0221 (cyclophosphamide/prednisone/rituximab) +
ganciclovir and cytogam 3. ANHL 01P1 group B w/ rituximab + ganciclovir and cytogam 4.
valganciclovir outpatient 5. ganciclovir and cytogam 6. during cells - 4 cycles gemcitabine +
vinorelbine 1. melphalan-dexamethasone 2. promace-cytabom x 6 3. infusions of EBV-specific T-cells generated by Kenneth Lucas from HLA identical sister 4. - 2 courses CHOP
1. 3 cycles of cyclophosphamide w/ rituximab; 2. two doses of high-dose methotrexate +
rituximab with leucovorin rescue 3. temozolomide Date Recue/Date Received 2021-05-11
rituximab); 2. 6 cycles gemcitabine/vinorelbine 1. 5 cycles R-CEOP 2. R-GEMOX 3. rituximab + bortezomib HD methotrexate & temozolomide w/ rituximab; cytarabine 1. rituximab/prednisone/ cyclophosphamide) 2.
vincristine/rituximab/cyclophosphamide 1. ANHL0131 (doxorubicin, vincristine, prednisone, IT methotrexate) 2.
vinblastine, CCNU, and ARA-C 3. ANHL01P1 (COP-R) 4. BEACOPP
1. Cyclophosphamide, prednisone, rituximab per ANHL0221 6 cycles R-CHOP; IT cytarabine; 5 day course IT methotrexate, ara-C, dexamethasone 3 cycles IVAC start 1. tonsillectomy/adenoidectomy 2. ANHL 0221 (cyclophosphamide/prednisone/rituximab) +
ganciclovir and cytogam 3. ANHL 01P1 group B w/ rituximab + ganciclovir and cytogam 4.
valganciclovir outpatient 5. ganciclovir and cytogam 6. during cells - 4 cycles gemcitabine +
vinorelbine 1. melphalan-dexamethasone 2. promace-cytabom x 6 3. infusions of EBV-specific T-cells generated by Kenneth Lucas from HLA identical sister 4. - 2 courses CHOP
1. 3 cycles of cyclophosphamide w/ rituximab; 2. two doses of high-dose methotrexate +
rituximab with leucovorin rescue 3. temozolomide Date Recue/Date Received 2021-05-11
Claims (126)
1. Use of a population of allogeneic T cells comprising EBV-specific T
cells for the preparation of a medicament for the treatment of an EBV-LPD (Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient; wherein the EBV-LPD is a disorder of cells of B cell lineage, wherein the EBV-LPD is resistant to (a) a combination chemotherapy to treat the EBV-LPD, (b) a therapy with an anti-CD20 monoclonal antibody to treat the EBV-LPD, and (c) a radiation therapy to treat the EBV-LPD, and wherein the population of allogeneic T cells is restricted by a human leukocyte antigen (HLA) allele shared with cells of the EBV-LPD.
cells for the preparation of a medicament for the treatment of an EBV-LPD (Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient; wherein the EBV-LPD is a disorder of cells of B cell lineage, wherein the EBV-LPD is resistant to (a) a combination chemotherapy to treat the EBV-LPD, (b) a therapy with an anti-CD20 monoclonal antibody to treat the EBV-LPD, and (c) a radiation therapy to treat the EBV-LPD, and wherein the population of allogeneic T cells is restricted by a human leukocyte antigen (HLA) allele shared with cells of the EBV-LPD.
2. The use of claim 1, wherein the combination chemotherapy comprises therapy with cyclophosphamide and prednisone.
3. The use of claim 2, wherein the combination chemotherapy comprises a low-dose cyclophosphamide and prednisone regimen.
4. The use of claim 1, wherein the combination chemotherapy comprises therapy with cyclophosphamide and methylprednisolone.
5. The use of claim 4, wherein the combination chemotherapy comprises a low-dose cyclophosphamide and methylprednisolone regimen.
6. The use of claim 1, wherein the EBV-LPD is resistant to multiple different combination chemotherapies to treat the EBV-LPD.
7. The use of claim 6, wherein at least one of the multiple different combination chemotherapies comprises therapy with cyclophosphamide and prednisone.
8. The use of claim 7, wherein at least one of the multiple different combination chemotherapies comprises a low-dose cyclophosphamide and prednisone regimen.
9. The use of claim 6, wherein at least one of the multiple different combination chemotherapies comprises therapy with cyclophosphamide and methylprednisolone.
Date Recue/Date Received 2022-11-16
Date Recue/Date Received 2022-11-16
10. The use of claim 9, wherein at least one of the multiple different combination chemotherapies comprises a low-dose cyclophosphamide and methylprednisolone regimen.
11. The use of any one of claims 1 to 10, wherein the anti-CD20 monoclonal antibody is rituximab.
12. The use of any one of claims 1 to 11, wherein the EBV-LPD is an EBV-positive lymphoma.
13. The use of any one of claims 1 to 11, wherein the EBV-LPD is diffuse large B-cell lymphoma.
14. The use of any one of claims 1 to 13, wherein the EBV-LPD is present in the central nervous system of the human patient.
15. The use of claim 14, wherein the EBV-LPD is present in the brain of the human patient.
16. The use of any one of claims 1 to 15, wherein prior to the treatment, at least one HLA allele of cells of the EBV-LPD has been ascertained by high-resolution typing.
17. The use of any one of claims 1 to 16, wherein the population of allogeneic T
cells shares with cells of the EBV-LPD at least 2 out of 8 HLA alleles that are typed.
cells shares with cells of the EBV-LPD at least 2 out of 8 HLA alleles that are typed.
18. The use of claim 17, wherein the 8 HLA alleles that are typed are two HLA-A
alleles, two HLA-B alleles, two HLA-C alleles, and two HLA-DR alleles.
alleles, two HLA-B alleles, two HLA-C alleles, and two HLA-DR alleles.
19. The use of any one of claims 1 to 18, wherein the EBV-specific T cells recognize an EBV antigen that is EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1 or LMP2.
20. The use of any one of claims 1 to 19, wherein the human patient has been the recipient of a solid organ transplant from a transplant donor.
21. The use of claim 20, wherein the solid organ transplant is a kidney transplant, a liver transplant, a heart transplant, an intestinal transplant, a pancreas transplant, a lung transplant, or a combination thereof.
Date Recue/Date Received 2022-11-16
Date Recue/Date Received 2022-11-16
22. The use of claim 20, wherein the solid organ transplant is a kidney transplant.
23. The use of claim 20, wherein the solid organ transplant is a liver transplant.
24. The use of any one of claims 1 to 19, wherein the human patient has been the recipient of a hematopoietic stem cell transplant from a transplant donor.
25. The use of claim 24, wherein the hematopoietic stem cell transplant is a bone marrow transplant, a peripheral blood stem cell transplant, or a cord blood transplant.
26. The use of any one of claims 20 to 25, wherein the population of allogeneic T
cells is derived from a donor other than the transplant donor.
cells is derived from a donor other than the transplant donor.
27. The use of any one of claims 1 to 19, wherein the human patient is infected with HIV.
28. The use of any one of claims 1 to 27, wherein the medicament is for administration to the human patient by infusion.
29. The use of claim 28, wherein the infusion is a bolus intravenous infusion.
30. The use of any one of claims 1 to 29, wherein the treatment comprises at least 1 x 105 T cells of the population of allogeneic T cells per kg of the human patient per dose per week.
31. The use of any one of claims 1 to 29, wherein the treatment comprises about 1 x 106 to about 2 x 106 T cells of the population of allogeneic T cells per kg of the human patient per dose per week.
32. The use of any one of claims 1 to 29, wherein the treatment comprises about 1 x 106 T cells of the population of allogeneic T cells per kg of the human patient per dose per week.
33. The use of any one of claims 1 to 29, wherein the treatment comprises about 2 x 106 T cells of the population of allogeneic T cells per kg of the human patient per dose per week.
Date Reçue/Date Received 2022-11-16
Date Reçue/Date Received 2022-11-16
34. The use of any one of claims 1 to 33, wherein the treatment comprises at least 2 doses of the population of allogeneic T cells.
35. The use of claim 34, wherein the treatment comprises 2, 3, 4, 5, or 6 doses of the population of allogeneic T cells.
36. The use of any one of claims 1 to 33, wherein the treatment comprises a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period of no dose of the population of allogeneic T
cells, followed by a second cycle of said one dose per week of the population of allogeneic T
cells for 3 consecutive weeks.
cells, followed by a second cycle of said one dose per week of the population of allogeneic T
cells for 3 consecutive weeks.
37. The use of any one of claims 1 to 33, wherein the treatment comprises two, three, four, five, or six cycles of one dose per week of the population of allogeneic T cells for 3 consecutive weeks, each treatment cycle separated by a washout period of no dose of the population of allogeneic T cells.
38. The use of claim 36 or 37, wherein the washout period is about three weeks.
39. The use of any one of claims 1 to 38, wherein the treatment comprises, after treatment with the population of allogeneic T cells, treatment with a second population of allogeneic T cells comprising EBV-specific T cells; wherein the second population of allogeneic T cells is restricted by a different HLA allele shared with cells of the EBV-LPD.
40. The use of claim 39, wherein the treatment comprises a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period of no dose of the population of allogeneic T cells, followed by a second cycle of one dose per week of the second population of allogeneic T cells for 3 consecutive weeks.
41. The use of claim 40, wherein the washout period is about three weeks.
42. The use of any one of claims 39 to 41, wherein the human patient has no response, an incomplete response, or a suboptimal response after the population of allogeneic T cells and prior to the second population of allogeneic T cells.
43. Use of a population of allogeneic T cells comprising EBV-specific T
cells for the treatment of an EBV-LPD in a human patient; wherein the EBV-LPD is a disorder of Date Recue/Date Received 2022-11-16 cells of B cell lineage, wherein the EBV-LPD is resistant to (a) a combination chemotherapy to treat the EBV-LPD, (b) a therapy with an anti-CD20 monoclonal antibody to treat the EBV-LPD, and (c) a radiation therapy to treat the EBV-LPD, and wherein the population of allogeneic T cells is restricted by an HLA allele shared with cells of the EBV-LPD.
cells for the treatment of an EBV-LPD in a human patient; wherein the EBV-LPD is a disorder of Date Recue/Date Received 2022-11-16 cells of B cell lineage, wherein the EBV-LPD is resistant to (a) a combination chemotherapy to treat the EBV-LPD, (b) a therapy with an anti-CD20 monoclonal antibody to treat the EBV-LPD, and (c) a radiation therapy to treat the EBV-LPD, and wherein the population of allogeneic T cells is restricted by an HLA allele shared with cells of the EBV-LPD.
44. The use of claim 43, wherein the combination chemotherapy comprises therapy with cyclophosphamide and prednisone.
45. The use of claim 44, wherein the combination chemotherapy comprises a low-dose cyclophosphamide and prednisone regimen.
46. The use of claim 43, wherein the combination chemotherapy comprises therapy with cyclophosphamide and methylprednisolone.
47. The use of claim 46, wherein the combination chemotherapy comprises a low-dose cyclophosphamide and methylprednisolone regimen.
48. The use of claim 43, wherein the EBV-LPD is resistant to multiple different combination chemotherapies to treat the EBV-LPD.
49. The use of claim 48, wherein at least one of the multiple different combination chemotherapies comprises therapy with cyclophosphamide and prednisone.
50. The use of claim 49, wherein at least one of the multiple different combination chemotherapies comprises a low-dose cyclophosphamide and prednisone regimen.
51. The use of claim 48, wherein at least one of the multiple different combination chemotherapies comprises therapy with cyclophosphamide and methylprednisolone.
52. The use of claim 51, wherein at least one of the multiple different combination chemotherapies comprises a low-dose cyclophosphamide and methylprednisolone regimen.
53. The use of any one of claims 43 to 52, wherein the anti-CD20 monoclonal antibody is rituximab.
54. The use of any one of claims 43 to 53, wherein the EBV-LPD is an EBV-positive lymphoma.
Date Recue/Date Received 2022-11-16
Date Recue/Date Received 2022-11-16
55. The use of any one of claims 43 to 53, wherein the EBV-LPD is diffuse large B-cell lymphoma.
56. The use of any one of claims 43 to 55, wherein the EBV-LPD is present in the central nervous system of the human patient.
57. The use of claim 56, wherein the EBV-LPD is present in the brain of the human patient.
58. The use of any one of claims 43 to 57, wherein prior to the treatment, at least one HLA allele of cells of the EBV-LPD has been ascertained by high-resolution typing.
59. The use of any one of claims 43 to 58, wherein the population of allogeneic T
cells shares with cells of the EBV-LPD at least 2 out of 8 HLA alleles that axe typed.
cells shares with cells of the EBV-LPD at least 2 out of 8 HLA alleles that axe typed.
60. The use of claim 59, wherein the 8 HLA alleles that are typed are two HLA-A
alleles, two HLA-B alleles, two HLA-C alleles, and two HLA-DR alleles.
alleles, two HLA-B alleles, two HLA-C alleles, and two HLA-DR alleles.
61. The use of any one of claims 43 to 60, wherein the EBV-specific T cells recognize an EBV antigen that is EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1 or LMP2.
62. The use of any one of claims 43 to 61, wherein the human patient has been the recipient of a solid organ transplant from a transplant donor.
63. The use of claim 62, wherein the solid organ transplant is a kidney transplant, a liver transplant, a heart transplant, an intestinal transplant, a pancreas transplant, a lung transplant, or a combination thereof.
64. The use of claim 62, wherein the solid organ transplant is a kidney transplant.
65. The use of claim 62, wherein the solid organ transplant is a liver transplant.
66. The use of any one of claims 43 to 61, wherein the human patient has been the recipient of a hematopoietic stem cell transplant from a transplant donor.
67. The use of claim 66, wherein the hematopoietic stem cell transplant is a bone marrow transplant, a peripheral blood stem cell transplant, or a cord blood transplant.
Date Recue/Date Received 2022-11-16
Date Recue/Date Received 2022-11-16
68. The use of any one of claims 62 to 67, wherein the population of allogeneic T
cells is derived from a donor other than the transplant donor.
cells is derived from a donor other than the transplant donor.
69. The use of any one of claims 43 to 61, wherein the human patient is infected with HIV.
70. The use of any one of claims 43 to 69, wherein the population of allogeneic T
cells is for administration to the human patient by infusion.
cells is for administration to the human patient by infusion.
71. The use of claim 70, wherein the infusion is a bolus intravenous infusion.
72. The use of any one of claims 43 to 71, wherein the treatment comprises at least 1 x 105 T cells of the population of allogeneic T cells per kg of the human patient per dose per week.
73. The use of any one of claims 43 to 71, wherein the treatment comprises about 1 x 106 to about 2 x 106 T cells of the population of allogeneic T cells per kg of the human patient per dose per week.
74. The use of any one of claims 43 to 71, wherein the treatment comprises about 1 x 106 T cells of the population of allogeneic T cells per kg of the human patient per dose per week.
75. The use of any one of claims 43 to 71, wherein the treatment comprises about 2 x 106 T cells of the population of allogeneic T cells per kg of the human patient per dose per week.
76. The use of any one of claims 43 to 75, wherein the treatment comprises at least 2 doses of the population of allogeneic T cells.
77. The use of claim 76, wherein the treatment comprises 2, 3, 4, 5, or 6 doses of the population of allogeneic T cells.
78. The use of any one of claims 43 to 75, wherein the treatment comprises a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period of no dose of the population of allogeneic T
cells, followed by Date Reçue/Date Received 2022-11-16 a second cycle of said one dose per week of the population of allogeneic T
cells for 3 consecutive weeks.
cells, followed by Date Reçue/Date Received 2022-11-16 a second cycle of said one dose per week of the population of allogeneic T
cells for 3 consecutive weeks.
79. The use of any one of claims 43 to 75, wherein the treatment comprises two, three, four, five, or six cycles of one dose per week of the population of allogeneic T cells for 3 consecutive weeks, each treatment cycle separated by a washout period of no dose of the population of allogeneic T cells.
80. The use of claim 78 or 79, wherein the washout period is about three weeks.
81. The use of any one of claims 43 to 80, wherein the treatment comprises, after treatment with the population of allogeneic T cells, treatment with a second population of allogeneic T cells comprising EBV-specific T cells; wherein the second population of allogeneic T cells is restricted by a different HLA allele shared with cells of the EBV-LPD.
82. The use of claim 81, wherein the treatment comprises a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period of no dose of the population of allogeneic T cells, followed by a second cycle of one dose per week of the second population of allogeneic T cells for 3 consecutive weeks.
83. The use of claim 82, wherein the washout period is about three weeks.
84. The use of any one of claims 81 to 83, wherein the human patient has no response, an incomplete response, or a suboptimal response after the population of allogeneic T cells and prior to the second population of allogeneic T cells.
85. A population of allogeneic T cells comprising EBV-specific T cells for use in the treatment of an EBV-LPD in a human patient; wherein the EBV-LPD is a disorder of cells of B cell lineage, wherein the EBV-LPD is resistant to (a) a combination chemotherapy to treat the EBV-LPD, (b) a therapy with an anti-CD20 monoclonal antibody to treat the EBV-LPD, and (c) a radiation therapy to treat the EBV-LPD, and wherein the population of allogeneic T cells is restricted by an HLA allele shared with cells of the EBV-LPD.
86. The population of allogeneic T cells for use of claim 85, wherein the combination chemotherapy comprises therapy with cyclophosphamide and prednisone.
Date Recue/Date Received 2022-11-16
Date Recue/Date Received 2022-11-16
87. The population of allogeneic T cells for use of claim 86, wherein the combination chemotherapy comprises a low-dose cyclophosphamide and prednisone regimen.
88. The population of allogeneic T cells for use of claim 85, wherein the combination chemotherapy comprises therapy with cy cl ophosphami de and methylprednisolone.
89. The population of allogeneic T cells for use of claim 86, wherein the combination chemotherapy comprises a low-dose cyclophosphamide and methylprednisolone regimen.
90. The population of allogeneic T cells for use of claim 85, wherein the EBV-LPD is resistant to multiple different combination chemotherapies to treat the EBV-LPD.
91. The population of allogeneic T cells for use of claim 90, wherein at least one of the multiple different combination chemotherapies comprises therapy with cyclophosphamide and prednisone.
92. The population of allogeneic T cells for use of claim 91, wherein at least one of the multiple different combination chemotherapies comprises a low-dose cyclophosphamide and prednisone regimen.
93. The population of allogeneic T cells for use of claim 90, wherein at least one of the multiple different combination chemotherapies comprises therapy with cyclophosphamide and methylprednisolone.
94. The population of allogeneic T cells for use of claim 93, wherein at least one of the multiple different combination chemotherapies comprises a low-dose cyclophosphamide and methylprednisolone regimen.
95. The population of allogeneic T cells for use of any one of claims 85 to 94, wherein the anti-CD20 monoclonal antibody is rituximab.
96. The population of allogeneic T cells for use of any one of claims 85 to 95, wherein the EBV-LPD is an EBV-positive lymphoma.
Date Recue/Date Received 2022-11-16
Date Recue/Date Received 2022-11-16
97. The population of allogeneic T cells for use of any one of claims 85 to 95, wherein the EBV-LPD is diffuse large B-cell lymphoma.
98. The population of allogeneic T cells for use of any one of claims 85 to 97, wherein the EBV-LPD is present in the central nervous system of the human patient.
99. The population of allogeneic T cells for use of claim 98, wherein the EBV-LPD is present in the brain of the human patient.
100. The population of allogeneic T cells for use of any one of claims 85 to 99, wherein prior to the treatment, at least one HLA allele of cells of the EBV-LPD has been ascertained by high-resolution typing.
101. The population of allogeneic T cells for use of any one of claims 85 to 100, wherein the population of allogeneic T cells shares with cells of the EBV-LPD
at least 2 out of 8 HLA alleles that are typed.
at least 2 out of 8 HLA alleles that are typed.
102. The population of allogeneic T cells for use of claim 101, wherein the 8 HLA
alleles that are typed are two HLA-A alleles, two HLA-B alleles, two HLA-C
alleles, and two HLA-DR alleles.
alleles that are typed are two HLA-A alleles, two HLA-B alleles, two HLA-C
alleles, and two HLA-DR alleles.
103. The population of allogeneic T cells for use of any one of claims 85 to 102, wherein the EBV-specific T cells recognize an EBV antigen that is EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1 or LMP2.
104. The population of allogeneic T cells for use of any one of claims 85 to 103, wherein the human patient has been the recipient of a solid organ transplant from a transplant donor.
105. The population of allogeneic T cells for use of claim 104, wherein the solid organ transplant is a kidney transplant, a liver transplant, a heart transplant, an intestinal transplant, a pancreas transplant, a lung transplant, or a combination thereof.
106. The population of allogeneic T cells for use of claim 104, wherein the solid organ transplant is a kidney transplant.
Date Recue/Date Received 2022-11-16
Date Recue/Date Received 2022-11-16
107. The population of allogeneic T cells for use of claim 104, wherein the solid organ transplant is a liver transplant.
108. The population of allogeneic T cells for use of any one of claims 85 to 103, wherein the human patient has been the recipient of a hematopoietic stem cell transplant from a transplant donor.
109. The population of allogeneic T cells for use of claim 108, wherein the hematopoietic stem cell transplant is a bone marrow transplant, a peripheral blood stem cell transplant, or a cord blood transplant.
110. The population of allogeneic T cells for use of any one of claims 104 to 109, wherein the population of allogeneic T cells is derived from a donor other than the transplant donor.
111. The population of allogeneic T cells for use of any one of claims 85 to 103, wherein the human patient is infected with HIV.
112. The population of allogeneic T cells for use of any one of claims 85 to 111, wherein the population of allogeneic T cells is for administration to the human patient by infusion.
113. The population of allogeneic T cells for use of claim 112, wherein the infusion is a bolus intravenous infusion.
114. The population of allogeneic T cells for use of any one of claims 85 to 113, wherein the treatment comprises at least 1 x 105 T cells of the population of allogeneic T cells per kg of the human patient per dose per week.
115. The population of allogeneic T cells for use of any one of claims 85 to 113, wherein the treatment comprises about 1 x 106 to about 2 x 106 T cells of the population of allogeneic T cells per kg of the human patient per dose per week.
116. The population of allogeneic T cells for use of any one of claims 85 to 113, wherein the treatment comprises about 1 x 106 T cells of the population of allogeneic T cells per kg of the human patient per dose per week.
Date Reçue/Date Received 2022-11-16
Date Reçue/Date Received 2022-11-16
117. The population of allogeneic T cells for use of any one of claims 85 to 113, wherein the treatment comprises about 2 x 106 T cells of the population of allogeneic T cells per kg of the human patient per dose per week.
118. The population of allogeneic T cells for use of any one of claims 85 to 117, wherein the treatment comprises at least 2 doses of the population of allogeneic T cells.
119. The population of allogeneic T cells for use of claim 118, wherein the treatment comprises 2, 3, 4, 5, or 6 doses of the population of allogeneic T
cells.
cells.
120. The population of allogeneic T cells for use of any one of claims 85 to 117, wherein the treatment comprises a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period of no dose of the population of allogeneic T cells, followed by a second cycle of said one dose per week of the population of allogeneic T cells for 3 consecutive weeks.
121. The population of allogeneic T cells for use of any one of claims 85 to 117, wherein the treatment comprises two, three, four, five, or six cycles of one dose per week of the population of allogeneic T cells for 3 consecutive weeks, each treatment cycle separated by a washout period of no dose of the population of allogeneic T cells.
122. The population of allogeneic T cells for use of claim 120 or 121, wherein the washout period is about three weeks.
123. The population of allogeneic T cells for use of any one of claims 85 to 122, wherein the treatment comprises, after treatment with the population of allogeneic T cells, treatment with a second population of allogeneic T cells comprising EBV-specific T cells;
wherein the second population of allogeneic T cells is restricted by a different HLA allele shared with cells of the EBV-LPD.
wherein the second population of allogeneic T cells is restricted by a different HLA allele shared with cells of the EBV-LPD.
124. The population of allogeneic T cells for use of claim 123, wherein the treatment comprises a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period of no dose of the population of allogeneic T cells, followed by a second cycle of one dose per week of the second population of allogeneic T cells for 3 consecutive weeks.
Date Reçue/Date Received 2022-11-16
Date Reçue/Date Received 2022-11-16
125. The population of allogeneic T cells for use of claim 124, wherein the washout period is about three weeks.
126. The population of allogeneic T cells for use of any one of claims 123 to 125, wherein the human patient has no response, an incomplete response, or a suboptimal response after the population of allogeneic T cells and prior to the second population of allogeneic T
cells.
Date Recue/Date Received 2022-11-16
cells.
Date Recue/Date Received 2022-11-16
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562160549P | 2015-05-12 | 2015-05-12 | |
US62/160,549 | 2015-05-12 | ||
PCT/US2016/031784 WO2016183153A1 (en) | 2015-05-12 | 2016-05-11 | Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2984178A1 CA2984178A1 (en) | 2016-11-17 |
CA2984178C true CA2984178C (en) | 2023-10-31 |
Family
ID=56027234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2984178A Active CA2984178C (en) | 2015-05-12 | 2016-05-11 | Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy |
Country Status (19)
Country | Link |
---|---|
US (1) | US10568908B2 (en) |
EP (1) | EP3294304B1 (en) |
JP (2) | JP7284556B2 (en) |
KR (1) | KR102666781B1 (en) |
CN (1) | CN107835690A (en) |
AR (1) | AR104598A1 (en) |
AU (1) | AU2016262484B2 (en) |
BR (1) | BR112017024431B1 (en) |
CA (1) | CA2984178C (en) |
CL (1) | CL2017002846A1 (en) |
FR (1) | FR23C1025I1 (en) |
HK (1) | HK1244697A1 (en) |
IL (1) | IL255581B (en) |
MX (1) | MX2017014257A (en) |
NZ (1) | NZ736675A (en) |
PH (1) | PH12017501993A1 (en) |
RU (1) | RU2720245C2 (en) |
WO (1) | WO2016183153A1 (en) |
ZA (1) | ZA201707335B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109477830A (en) | 2016-05-25 | 2019-03-15 | 昆士兰医学研究所理事会 | The method of immunotherapy |
KR102501827B1 (en) * | 2016-09-16 | 2023-02-22 | 베이롤 칼리지 오브 메드신 | Platform for activation and expansion of virus-specific T-cells |
CA3074516A1 (en) | 2017-10-23 | 2019-05-02 | Atara Biotherapeutics, Inc. | Methods of managing tumor flare in adoptive immunotherapy |
CN108220237B (en) * | 2017-12-20 | 2020-11-06 | 中国科学院遗传与发育生物学研究所 | Human NK/T cell line |
WO2019136379A1 (en) * | 2018-01-08 | 2019-07-11 | Atara Biotherapeutics, Inc. | Systems and methods for distributing cell therapies |
EP3765602A1 (en) | 2018-03-14 | 2021-01-20 | Memorial Sloan Kettering Cancer Center | Methods of selecting t cell line for adoptive cellular therapy |
KR20220092905A (en) * | 2019-10-23 | 2022-07-04 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | Adoptive Immunotherapy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPO784197A0 (en) * | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
US7163685B2 (en) * | 2003-04-16 | 2007-01-16 | City Of Hope | Human cytomegalovirus antigens expressed in MVA and methods of use |
JP4824389B2 (en) * | 2005-10-28 | 2011-11-30 | 株式会社医学生物学研究所 | Cytotoxic T cell epitope peptide that specifically attacks Epstein-Barr virus infected cells and uses thereof |
EP2365823B1 (en) * | 2008-10-30 | 2016-11-30 | Yeda Research And Development Company Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
EP2611905A4 (en) | 2010-09-01 | 2014-02-12 | Baylor College Medicine | Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc) |
BR112014027957A8 (en) * | 2012-05-08 | 2018-01-16 | Univ Johns Hopkins | methods and compositions for infusion of selected populations of transient allogeneic lymphocyte graft to treat cancer " |
JP2015533366A (en) * | 2012-10-19 | 2015-11-24 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | Improved human herpesvirus immunotherapy |
EP3060059A4 (en) * | 2013-10-25 | 2017-11-01 | Board of Regents, The University of Texas System | Polyclonal gamma delta t cells for immunotherapy |
MX2017005707A (en) * | 2014-11-05 | 2017-08-21 | Memorial Sloan Kettering Cancer Center | Methods of selecting t cell line and donor thereof for adoptive cellular therapy. |
WO2017003763A1 (en) * | 2015-06-27 | 2017-01-05 | Memorial Sloan Kettering Cancer Center | Methods of treating glioblastoma multiforme by t cell therapy |
-
2016
- 2016-05-11 EP EP16724230.4A patent/EP3294304B1/en active Active
- 2016-05-11 WO PCT/US2016/031784 patent/WO2016183153A1/en active Application Filing
- 2016-05-11 KR KR1020177034692A patent/KR102666781B1/en active IP Right Grant
- 2016-05-11 RU RU2017143151A patent/RU2720245C2/en active
- 2016-05-11 JP JP2017559029A patent/JP7284556B2/en active Active
- 2016-05-11 MX MX2017014257A patent/MX2017014257A/en unknown
- 2016-05-11 AU AU2016262484A patent/AU2016262484B2/en active Active
- 2016-05-11 CA CA2984178A patent/CA2984178C/en active Active
- 2016-05-11 NZ NZ736675A patent/NZ736675A/en unknown
- 2016-05-11 BR BR112017024431-4A patent/BR112017024431B1/en active IP Right Grant
- 2016-05-11 AR ARP160101364A patent/AR104598A1/en unknown
- 2016-05-11 CN CN201680039509.4A patent/CN107835690A/en active Pending
- 2016-05-11 US US15/572,557 patent/US10568908B2/en active Active
-
2017
- 2017-10-27 ZA ZA2017/07335A patent/ZA201707335B/en unknown
- 2017-11-02 PH PH12017501993A patent/PH12017501993A1/en unknown
- 2017-11-09 IL IL255581A patent/IL255581B/en active IP Right Grant
- 2017-11-10 CL CL2017002846A patent/CL2017002846A1/en unknown
-
2018
- 2018-03-28 HK HK18104239.3A patent/HK1244697A1/en unknown
-
2021
- 2021-04-19 JP JP2021070234A patent/JP2021119154A/en active Pending
-
2023
- 2023-06-14 FR FR23C1025C patent/FR23C1025I1/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL255581B (en) | 2021-03-25 |
RU2720245C2 (en) | 2020-04-28 |
NZ736675A (en) | 2023-03-31 |
ZA201707335B (en) | 2021-02-24 |
JP2021119154A (en) | 2021-08-12 |
BR112017024431B1 (en) | 2021-10-13 |
KR102666781B1 (en) | 2024-05-20 |
CA2984178A1 (en) | 2016-11-17 |
US10568908B2 (en) | 2020-02-25 |
RU2017143151A3 (en) | 2019-10-29 |
MX2017014257A (en) | 2018-04-20 |
IL255581A (en) | 2018-01-31 |
HK1244697A1 (en) | 2018-08-17 |
EP3294304A1 (en) | 2018-03-21 |
WO2016183153A1 (en) | 2016-11-17 |
EP3294304B1 (en) | 2020-01-29 |
AU2016262484B2 (en) | 2021-10-21 |
JP2018520095A (en) | 2018-07-26 |
US20180125891A1 (en) | 2018-05-10 |
BR112017024431A2 (en) | 2018-07-24 |
JP7284556B2 (en) | 2023-05-31 |
AU2016262484A1 (en) | 2018-01-04 |
RU2017143151A (en) | 2019-06-13 |
FR23C1025I1 (en) | 2023-07-21 |
PH12017501993A1 (en) | 2018-03-26 |
KR20180003575A (en) | 2018-01-09 |
CN107835690A (en) | 2018-03-23 |
CL2017002846A1 (en) | 2018-05-25 |
AR104598A1 (en) | 2017-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2984178C (en) | Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy | |
US20220160729A1 (en) | Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy | |
EP4045083A1 (en) | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia | |
TWI759270B (en) | Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy | |
WO2017003763A1 (en) | Methods of treating glioblastoma multiforme by t cell therapy | |
EA043393B1 (en) | REPLACEMENT OF CYTOTOXIC PRECONDITIONING BEFORE CELLULAR IMMUNOTHERAPY | |
Sobecks et al. | Platelet Engraftment in AML Patients Receiving Matched Related Donor (MRD) Allogeneic Bone Marrow Transplant (alloBMT) Correlates with Major Histocompatibility Complex Class I-Related Molecule A (MICA) Gene Polymorphisms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20210511 |
|
EEER | Examination request |
Effective date: 20210511 |
|
EEER | Examination request |
Effective date: 20210511 |
|
EEER | Examination request |
Effective date: 20210511 |
|
EEER | Examination request |
Effective date: 20210511 |
|
EEER | Examination request |
Effective date: 20210511 |